Podcasts about Literature review

We have done some research recently on the incidence of MUA after TKA: Women This is considered a Literature Review.

Executive Summary:This document summarizes key instructions and guidelines provided for the completion of the first draft of the thesis paper and preparation for the mock presentations. The sources emphasize adherence to formatting requirements (APA 7th edition), content guidelines for specific sections (Abstract, Introduction, Literature Review, Method, Results/Discussion, Conclusion, Appendices, References), and preparation strategies for the mock presentations, including content, delivery, and technical aspects. Key themes include attention to detail in formatting, summarizing the paper effectively, and practicing delivery and anticipating questions for the presentation.Key Themes and Ideas:* Hard Copy Draft Review: Students are required to submit a hard copy of their first completed draft. A quick self-review in groups is encouraged, focusing on specific formatting elements.* Headings: Check that all headings (except in the method section) have 6 to 12 words. Main words should be capitalized. No punctuation should be at the end of any heading. Method section headings (Participants, Instruments, Procedure, Data Analysis) can be shorter.* Page Breaks: Specific pages should be on their own page: Title page, Authorization page, Abstract, Table of Contents, Figures/Tables (if applicable), and each Appendix. The body of the paper (Literature Review through the Conclusion paragraph) should have no page breaks.* Spacing: The entire paper should be double-spaced, with no extra space between paragraphs, headings, and text. References are an exception, with single spacing within the reference and double spacing between references.* Indentation: Each paragraph, except for the Abstract, should have a half-inch indentation.* Paragraph Count: The Abstract, Participants, Instruments, Procedure, and Data Analysis sections should each consist of only one paragraph. The final paragraph of the paper is considered the Conclusion paragraph and does not require a separate "Conclusion" heading.* Appendix Formatting: Each appendix should start on a new page with a Level 1 heading (e.g., "Appendix A") at the very top line, followed by a Level 2 heading for the appendix title.* Title Recommendations: The instructor suggests using ChatGPT to generate title ideas now that the paper is mostly complete.* If the title is longer than one line, force a return to distribute words more or less equally across two lines.* Single-space the title.* Improving Writing (Verb Usage): Students are encouraged to review their paper for overuse of the verbs "to have," "to be," and "to make" (as lexical verbs). While not forbidden, excessive use may indicate areas for improvement by substituting more dynamic verbs, often converting nouns into verbs. The instructor provides an example of how to rewrite sentences to be more concise and dynamic.* Mock Presentation Structure and Timing: The mock presentation is 20 minutes long with a 10-minute Q&A. The entire class scheduled for a specific day is expected to observe all presentations on that day.* Suggested Slide Order: Title slide, Problem and Purpose, Literature Review (multiple slides), Method, Results and Discussion (multiple slides), Conclusions, Thank You.* Approximate Timing: Problem and Purpose (30 seconds to 1 minute), Literature Review (approximately 8 minutes), Method (approximately 2 minutes), Results and Discussion (approximately 9-10 minutes).* Presentation Content: Present only the essential information that directly relates to the research questions and analyzed data. Do not attempt to present everything from the written paper due to time constraints.* Mock Presentation Delivery and Technical Aspects:* Preparation: Practice the presentation, ideally recording oneself and timing each section. Consider practicing in front of someone.* Slides: Slides are meant to support the speaker, not to be read directly. They should function as "big note cards" with key points or ideas. Each slide should focus on one main point and include a heading. Avoid paragraphs and excessive text on slides.* Visuals: Make slides visually appealing but not distracting. Use visuals like graphs, charts, tables, and images from the paper, simplifying or modifying them for the presentation. Use no more than three different font styles and sizes, and choose easy-to-read fonts. Avoid animations and complex color schemes that might reduce contrast.* Technology: Coordinate with classmates to use one computer for presentations on a given day. Test equipment beforehand, turn off automatic updates, and ensure the computer is fully charged and doesn't go to sleep. Have a backup of the presentation file (e.g., on a USB drive in addition to the computer).* Delivery: Focus on the message, not personal nervousness. Maintain eye contact with the audience, specifically the examiners during the final defense, distributing attention among them. Bring a water bottle.* Anticipate Questions: Prepare for potential questions, including definitions of key terms used in the study.* Final Oral Defense Considerations:* Similar guidelines to the mock presentation, but attendance is by invitation only (family, friends, classmates).* Coordinate bringing refreshments for the examiners.* Arrive at least 30 minutes early with guests.* Maintain eye contact, especially with examiners.* No microphone is expected to be needed; speak loudly and project.* Present from the stage or on the floor in front of the stage, based on comfort.* Paper Submission: Submit three hard copies of the first completed draft. Confirm that the version in Microsoft Teams is the same as the hard copy. The final paper (Word document and three hard copies) is due officially one week before the scheduled presentation.Quotes:* "Make sure that the headings all of the headings have 6 to 12 words except for the headings in the method section."* "Check each heading to make sure that the main words are capitalized."* "Finally, check at the end of each heading. No punctuation, no period, no colon, no. Nothing."* "The body of the paper, there are no page brakes."* "Make sure each appendix has a page break and appears at the very top line."* "Make sure that each paragraph with the exception of the abstract has a half of an inch indentation."* "Look at the abstracts. Each section of the method and your conclusion to make sure you only have one paragraph."* "Today, I'm going to receive your uh hard copies of your first completed draft. This is an important milestone, right?"* "Today I want to spend just a few minutes very quickly all of us taking a look at your document, making a few notes very very quick."* "I would recommend trying and experimenting with chatt to give you some ideas of titles now that your paper has been completed."* "If your title extends longer than one line... force a return... single space the title."* "I want you to see how many times you're using three birds. to have, to be, to make."* "The problem in general is when we're using a bunch of times these verbs voice passive and there is there are. The problem is we have a lot of nouns that could be converted to a verb."* "We need to be prepared on Monday, well, whenever you're presenting, for a 20 minute presentation with a 10 minute question and answer."* "Remember your presentation is there to support what you are saying, not vice versa."* "Think of the the PowerPoint presentation the slides as big cards note cards."* "We don't want any distractions, right? It's a distraction when you're speaking and somebody's coming in and out."* "Maintain eye contact... try to connect to those examiners because they're the ones that are going to give you the grades."Source 2: Excerpts from "TS Recap 15.mp4"This source provides a recap of Week 15 for Thesis Seminar, focusing on the requirements for the first completed draft of the thesis paper due the same week.Key Themes and Ideas:* First Completed Draft Requirements: The first completed draft is due as a hard copy. Students should refer to the course guidelines for detailed requirements, including approximate word counts.* Introduction Paragraph: Should start with a hook, provide context for the problem, and end with the thesis statement.* Transitional Paragraph: Should restate the thesis statement, summarize the problem, introduce the research questions, and conclude with a closing statement.* Conclusion Paragraph (End of Results and Discussion): Approximately 250 words. Should begin by restating and rewording the thesis statement, discuss study limitations and significance, suggest future research, and end with a closing statement.* Abstract: Should be on its own page, follow the provided template, and be one paragraph of approximately 250 words. It should summarize the entire paper: problem, method (participants, data collection, analysis), findings, and conclusions/implications. It serves as a snapshot for readers to decide if they want to read the full paper.* Formatting (Reinforced):Title: 6 to 12 words.* Spacing: Double-spaced throughout the paper (except references).* Alignment: Left-justified.* Indentation: 0.5-inch indentation for all paragraphs except the Abstract.* References: Adhere to APA 7th edition. Use a hanging indent (French indentation). Single-space within each reference and double-space between references.* Appendices: Each appendix on a new page with a Level 1 heading ("Appendix A," etc.) and a Level 2 heading for the title. Use the specified font styles (Level 1 APA, Level 2 APA, etc.) for headings.* Table of Contents: Should be updatable based on correctly formatted headings.* Approximate Word Counts: Provides word count guidelines for major sections: Literature Review (approx. 2250 words), Results and Discussion (approx. 2250 words), Method (approx. 500 words, divided among Participants, Instruments and Procedure, Data Analysis).Quotes:* "This week, we need to finish our first draft. And today, I want to talk about what should be included in your completed first draft. Uh a hard copy that you're to turn in by noon this Thursday, May 22nd, 2025."* "Make sure that you've uh reviewed the course guidelines that are available in Microsoft Teams... it includes a section with approximate word counts."* "Your paper should include an introductory or an introduction paragraph... make sure that the uh the introduction paragraph begins with a hook. It offers the context of the problem and it concludes by stating your thesis statement."* "The conclusion paragraph to end your results and discussion section should be approximately 250 words and begin again with your thesis statement restated and rewarded."* "After restating your thesis statement, you can talk about um any limitations that you find... include the significance of your study and also future research."* "The abstract should be on its own page... Should be one paragraph, approximately 250 words, and should state basically summarize uh your whole paper."* "Think of the abstract as a kind of a snapshot of your whole paper."* "Make sure you have a title of your paper, 6 to 12 words."* "Your whole paper should be double spaced, left justified."* "All paragraphs should have a uh 0.5 in indentation with the exception of the abstract."* "Double check your list of references making sure that they adhere to APA 7th edition."* "Make sure you using a French indentation or a uh a hanging indent."* "Each appendix should have a level one heading that states which appendix it is... And then as a level two, I would include the title of the of the appendix."Conclusion:Both sources provide essential guidance for completing the thesis paper draft and preparing for the mock presentations. The first source delves deeply into specific formatting checks and detailed presentation strategies, while the second source provides a concise overview of the key components and formatting requirements for the written draft. Students are strongly encouraged to meticulously review their drafts against the provided guidelines, practice their presentations thoroughly, and anticipate questions to ensure a successful mock presentation and final defense. Attention to detail in both the written document and the presentation delivery is paramount.Recap for Week 15Configuring tables and figures This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit benjaminlstewart.substack.com

Wieder mehr Freude an den kleinen Dingen? Dopamin-Detox oder Dopamin-Fasten soll es möglich machen. In dieser Folge erklärt Bent Freiwald, warum dieser Trend auf einem Trugschluss basiert. Und natürlich, wie es besser geht! Hier geht´s zur Folge: Warum du dein Handy nicht weglegen kannstHier geht's zum gleichnamigen Newsletter: Das Leben des BrainSchreibt uns Feedback an: brain@acbstories.comLinks zu Quellen und verwendeten Studien:1. A Literature Review on Holistic Well-Being and Dopamine Fasting: An Integrated Approach2. How to Feel Nothing Now, in Order to Feel More Later3. Dopamine and mental experience4. Effect of fasting on dopamine neurotransmission in subregions of the nucleus accumbens in male and female mice5. The Definitive Guide to Dopamine Fasting 2.0 - The Hot Silicon Valley Trend Hosted on Acast. See acast.com/privacy for more information.

Raphael Coelho e Ênio Macedo convidam Guilherme Kenzo para falar sobre abordagem de suicídio no PS em três casos.Precisa de ajuda? Ligue 188 - Centro de valorização da vida.Referências:1. Stene-Larsen, Kim, and Anne Reneflot. “Contact with primary and mental health care prior to suicide: A systematic review of the literature from 2000 to 2017.” Scandinavian journal of public health vol. 47,1 (2019): 9-17. doi:10.1177/14034948177462742. Walby, Fredrik A et al. “Contact With Mental Health Services Prior to Suicide: A Systematic Review and Meta-Analysis.” Psychiatric services (Washington, D.C.) vol. 69,7 (2018): 751-759. doi:10.1176/appi.ps.2017004753. Sher, L. “Preventing suicide.” QJM : monthly journal of the Association of Physicians vol. 97,10 (2004): 677-80. doi:10.1093/qjmed/hch1064. Domaradzki, Jan. “The Werther Effect, the Papageno Effect or No Effect? A Literature Review.” International journal of environmental research and public health vol. 18,5 2396. 1 Mar. 2021, doi:10.3390/ijerph180523965. https://www.planalto.gov.br/ccivil_03/leis/leis_2001/l10216.htm#:~:text=LEI%20No%2010.216%2C%20DE,modelo%20assistencial%20em%20sa%C3%BAde%20mental6. https://mpce.mp.br/wp-content/uploads/2018/04/20180061-OMS-Prevencao-do-Suicidio-Manual-para-profissionais-da-midia.pdf7. Niederkrotenthaler, Thomas et al. “Role of media reports in completed and prevented suicide: Werther v. Papageno effects.” The British journal of psychiatry : the journal of mental science vol. 197,3 (2010): 234-43. doi:10.1192/bjp.bp.109.0746338. Phillips, D P. “The influence of suggestion on suicide: substantive and theoretical implications of the Werther effect.” American sociological review vol. 39,3 (1974): 340-54.9. Jack, Belinda. “Goethe's Werther and its effects.” The lancet. Psychiatry vol. 1,1 (2014): 18-9. doi:10.1016/S2215-0366(14)70229-910. Jack, Belinda. “Goethe's Werther and its effects.” The lancet. Psychiatry vol. 1,1 (2014): 18-9. doi:10.1016/S2215-0366(14)70229-911. Guinovart, Martí et al. “Towards the Influence of Media on Suicidality: A Systematic Review of Netflix's 'Thirteen Reasons Why'.” International journal of environmental research and public health vol. 20,7 5270. 27 Mar. 2023, doi:10.3390/ijerph2007527012. Cipriani, Andrea et al. “Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis.” BMJ (Clinical research ed.) vol. 346 f3646. 27 Jun. 2013, doi:10.1136/bmj.f364613. BOTEGA, Neury Jose. Crise Suicida: Avaliação e manejo. Porto Alegre: Artmed, 2015.14. Seena Fazel, Bo Runeson. Suicide. N Engl J Med 2020;382:266-274. DOI: 10.1056/NEJMra190294415. Gustavo Turecki et al. Suicide and suicide risk. Nat Rev Dis Primers. 2019. Oct 24;5(1):74. doi: 10.1038/s41572-019-0121-0.16. https://www.setembroamarelo.com/17. Cartilha de prevenção de suicídio: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/cartilhas/2024/cartilha-prevencao-de-suicidios.pdf/view18. Baldaçara L, Rocha GA, Leite VDS, Porto DM, Grudtner RR, Diaz AP, Meleiro A, Correa H, Tung TC, Quevedo J, da Silva AG. Brazilian Psychiatric Association guidelines for the management of suicidal behavior. Part 1. Risk factors, protective factors, and assessment. Braz J Psychiatry. 2021 Sep-Oct;43(5):525-537. doi: 10.1590/1516-4446-2020-0994. PMID: 33111773; PMCID: PMC8555650. - https://pubmed.ncbi.nlm.nih.gov/33111773/19. Baldaçara L, Grudtner RR, da S Leite V, Porto DM, Robis KP, Fidalgo TM, Rocha GA, Diaz AP, Meleiro A, Correa H, Tung TC, Malloy-Diniz L, Quevedo J, da Silva AG. Brazilian Psychiatric Association guidelines for the management of suicidal behavior. Part 2. Screening, intervention, and prevention. Braz J Psychiatry. 2021 Sep-Oct;43(5):538-549. doi: 10.1590/1516-4446-2020-1108. Erratum in: Braz J Psychiatry. 2021 Sep-Oct;43(5):563. doi: 10.1590/1516-4446-2020-0025. PMID: 33331533; PMCID: PMC8555636. - https://pubmed.ncbi.nlm.nih.gov/33331533/20. https://cvv.org.br/wp-content/uploads/2023/08/manual_prevencao_suicidio_profissionais_saude.pdf21. https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/edicoes/2024/boletim-epidemiologico-volume-55-no-04.pdf

Many Ways For You To Stay Connected! Website: https://www.qualscholars.com/theinstitute/ Instagram: @qual_scholars Business Inquiries Only: contact@marvettelacy.com I help doctoral students finish their dissertations in 12 months by teaching them how to consistently follow the Scholar Writing Routine. #QualScholars #OfficeHoursWithDrLacy #FinishYourDissertation #QSInstitute __________ Dr. Marvette Lacy Ph.D., (she/her) is the founder and CEO of Qual Scholars, where she helps higher education folks finish their dissertations and start a profitable consulting business. Dr. Lacy started her business as a doctoral student looking for more freedom outside of the confines of the ivory tower. She wanted a life where she could design her days on her terms while doing work she loved. Dr. Lacy's research uses critical theories to explore the identity development of college women, the dynamics of power and privilege in sexual violence and response movements, and the intersections of race and gender in student activism. Dr. Lacy's Student Affairs professional background is mainly within Higher Education areas such as residence life and housing, student conduct, campus-based women's centers, and first-year programs. Dr. Lacy left Higher Education in 2020 to pursue full-time entrepreneurship. Dr. Lacy lives in the Atlanta area with her adorable puppy, Sir.

Welcome to the Social-Engineer Podcast: The Doctor Is In Series – where we will discuss understandings and developments in the field of psychology.   In today's episode, Chris and Abbie are discussing the Bystander Effect. They will talk about the many different ways it presents itself as well as how to avoid it and what you can do if you find yourself victim of it. [March 3, 2025]   00:00 - Intro 00:14 - Dr. Abbie Maroño Intro 00:45 - Intro Links -          Social-Engineer.com - http://www.social-engineer.com/ -          Managed Voice Phishing - https://www.social-engineer.com/services/vishing-service/ -          Managed Email Phishing - https://www.social-engineer.com/services/se-phishing-service/ -          Adversarial Simulations - https://www.social-engineer.com/services/social-engineering-penetration-test/ -          Social-Engineer channel on SLACK - https://social-engineering-hq.slack.com/ssb -          CLUTCH - http://www.pro-rock.com/ -          innocentlivesfoundation.org - http://www.innocentlivesfoundation.org/                                 03:06 - The Topic of the Day: The Bystander Effect 03:16 - Defining the Bystander Effect 05:14 - The Smoke Filled Room 09:03 - The Advantage of CCTV 11:13 - The Ambiguity Factor 12:53 - Gender Dynamics 15:20 - Self-Construal 16:43 - Reverse the Roles 21:21 - Bystanding Online 22:59 - It's Easier to be Negative 25:34 - Fear Factor 27:53 - Assigning Responsibility 30:34 - Education is Key 31:19 - Just Ask! 32:40 - Wrap Up 32:49 - Next Month: Why Do We Cry? 33:12 - Outro     -          www.social-engineer.com -          www.innocentlivesfoundation.org   Find us online: -          Twitter: @DrAbbieofficial -          LinkedIn: linkedin.com/in/dr-abbie-maroño-phd -          Instagram: @DoctorAbbieofficial -          Twitter: @humanhacker -          LinkedIn: linkedin.com/in/christopherhadnagy     References: Bauman, S., Yoon, J., Iurino, C., & Hackett, L. (2020). Experiences of adolescent witnesses to peer victimization: The bystander effect. Journal of school psychology, 80, 1-14. Fadilah, I. N., & Ansyah, E. H. (2022). The Relationship Between The Bystander Effect and Prososial Behavior in Students Of The Faculty Of Psychology And Educational Sciences At University. Academia Open, 7, 10-21070. Ganti, N., & Baek, S. (2021). Why People Stand By: A Comprehensive Study About the Bystander Effect. Journal of Student Research, 10(1). Havlik, J. L., Vieira Sugano, Y. Y., Jacobi, M. C., Kukreja, R. R., Jacobi, J. H. C., & Mason, P. (2020). The bystander effect in rats. Science Advances, 6(28), eabb4205. Kettrey, H. H., & Marx, R. A. (2021). Effects of bystander sexual assault prevention programs on promoting intervention skills and combatting the bystander effect: A systematic review and meta-analysis. Journal of experimental criminology, 17, 343-367. Levine, M., Philpot, R., & Kovalenko, A. G. (2020). Rethinking the bystander effect in violence reduction training programs. Social Issues and Policy Review, 14(1), 273-296. Liu, D., Liu, X., & Wu, S. (2022, June). A Literature Review of Diffusion of Responsibility Phenomenon. In 2022 8th International Conference on Humanities and Social Science Research (ICHSSR 2022) (pp. 1806-1810). Atlantis Press. Machackova, H. (2020). Bystander reactions to cyberbullying and cyberaggression: individual, contextual, and social factors. Current opinion in psychology, 36, 130-134. Madden, C., & Loh, J. (2020). Workplace cyberbullying and bystander helping behaviour. The International Journal of Human Resource Management, 31(19), 2434-2458. Szekeres, H., Halperin, E., Kende, A., & Saguy, T. (2022). Aversive Bystander Effect: Egalitarian bystanders' overestimation of confronting prejudice.

JCO PO author Dr. Hatim Husain at University of California San Diego, shares insights into his JCO PO article, “Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review”, one of the top downloaded articles of 2024. Host Dr. Rafeh Naqash and Dr. Husain discuss how to utilize real-world and clinical trial data to discern the safety of adagrasib (another KRASG12C inhibitor), following sotorasib discontinuation due to hepatotoxicity. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations where we bring you engaging conversations with authors of clinically relevant and highly significant JCOPO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Stephenson Cancer Center.  Today, I'm very excited to be joined by Dr. Hatim Hussain, Professor of Medicine at the University of California, San Diego, and author of the JCO Precision Oncology article, “Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS-G12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review.” This was one of the top downloaded articles of 2024. And the other interesting thing is we generally don't do podcasts for case reports or case series, so this is one of the very few that we have selected for the podcast.  And at the time of the recording, our guest disclosures will be linked in the transcript.  Dr. Hussain, welcome to our podcast and thank you for joining us today. Dr. Hatim Husain: Thank you Dr. Naqash. Such a pleasure to be here and to speak with you all. Dr. Rafeh Naqash: And for the sake of this podcast, we'll refer to each other using our first names. So again, as I mentioned earlier that this is one of the very few case reports that we have selected for podcasts in JCOPO and the intention was very deliberate because it caters to something that is emerging where we are trying to treat more KRAS mutant patients with different KRAS inhibitors. And you tried to address one very unique aspect of it in this article which pertains to toxicity, especially hepatotoxicity. So for the sake of our listeners who tend to be community oncologists, trainees, academic faculty, can you tell us what are KRAS inhibitors? What is KRAS-G12C? And how do some of these approved KRAS inhibitors try to inhibit KRAS-G12C? Dr. Hatim Husain: Sure. For a long time actually we've not had a selective way to inhibit mutant KRAS. And over the last several years actually now, we've seen some dramatic advances here, particularly with the FDA approval of some of the selective inhibitors against the G12C variant. So KRAS-G12C is an isoform of KRAS that is most common in lung cancer and in fact actually is a transversion mutation in the KRAS gene that is a product of the carcinogen of tobacco. And in fact, the incidence of KRAS-G12C in lung cancer, it's quite astounding where as many KRAS-G12C patients there are, there can be, as you know, more than EGFR patients in certain populations and cohorts. The medicines sotorasib and adagrasib were rationally designed to be selective KRAS-G12C inhibitors. And the way that they do this is that they lock the KRAS protein in the OFF state. KRAS is a protein that oscillates between an ON and an OFF state and by virtue of locking the protein in an OFF state, it has shown inhibition of downstream signaling and mitigation of tumor growth and, in fact, tumor cell death. Dr. Rafeh Naqash: I absolutely love the way you describe the ON and OFF state, the oscillation where the ON is bound to the GTP and the OFF is bound to the GDP. The two KRAS inhibitors as currently FDA approved, as you mentioned, are RAS OFF inhibitors and they're emerging KRAS inhibitors that are RAS ON. So now, as we have known from previous data related to immunotherapy and EGFR TKIs such as osimirtinib where toxicity tends to be a compounded effect when you have osimertinib given within a certain timeline of previous checkpoint therapy, we've seen that in the clinic as the data for these KRAS inhibitors is emerging, you talk about some very interesting aspects and data about what has been published so far with regards to prior use of immunotherapy or chemo immunotherapy and the subsequent use of KRAS inhibitors. Could you elaborate upon that? Dr. Hatim Husain: Sure. So for this population of patients, the first line approved strategy is a strategy that most cases will incorporate immune therapy and chemotherapy. Immune therapy can have some important responses for patients with KRAS-G12C. This may be due to the fact that KRAS-G12C patients may have a higher incidence of prior smoking, perhaps higher mutation burdens in some patients, and perhaps immunogenicity is defined in that context. So the standard of care in the first line currently includes immune therapy or immune therapy and chemotherapy. Where the current FDA approvals for selective G12C inhibitors are are after the first line of therapy. There are a number of trials exploring these medicines in the first line to see if they may be incorporated into a future treatment paradigm. Dr. Rafeh Naqash: Thank you for that explanation. Now, going to what you published in this manuscript, can you help us understand the context of why you looked at this? Even though the data just comprises a case series of a handful of patients, but the observations are very interesting and these are real world scenarios where we often tend to be in situations where an individual has had toxicity on a certain drug and may have some response to that drug, but at the same time, the toxicity is challenging. And then you try to debate whether another drug in the same class might be beneficial without those toxicities. So you've tried to address that to some extent using this data set. So can you elaborate upon the question, the methodology, what you tried to look at, and important observations that you have? Dr. Hatim Husain: Yes, our paper was actually inspired by one of my patients. My patient was a patient who had received chemotherapy and immune therapy and actually in the past, even, you know, additional lines of immune therapies, it was really coming to the edge of where standard treatments would exist. It was right at the same time that these selective inhibitors had been approved and the patient had received sotorasib. And what was remarkable was, when given sotorasib, patient had a very high peak and spike in the transaminases. And we would do different trials of strategies around dose, around interruptions. And it was becoming quite difficult, actually, for the patient to proceed with additional therapy. It was around similar times, actually, and I do want to make a note that the patient was progressing, driven in large fact by the fact that we've had to interrupt the medicine. So we feel and believe that the patient had had inadequate dosing because of the level of toxicity that the patient was having with transaminase increase. So it was around the same time that adagrasib was first commercially available that we were at that point, and we did a trial of adagrasib post-sotorasib, largely driven by necessity, without having additional options to provide this patient in our environment. What was remarkable was when the patient received the adagrasib, there were no spikes in transaminases similar to what we had seen before. And that really led us thinking and to say, “Is this adverse event of transaminase increase or hepatotoxicity, is this a class effect with KRAS-G12C inhibitors, or is it more nuanced than that? Are there different, perhaps, mechanisms by which the medicines may work that may more or less differentially contribute to this adverse event?” And so that inspired us to kind of do a larger analysis, kind of really reach out to a larger network of physicians to gather insights and to gather responses in patients who had had a serial approach of sotorasib and then adagrasib.  What we found in this process was, in fact, actually there were many more cases of patients who resembled my patient, where the sequence of sotorasib going to adagrasib may have demonstrated differential contribution of hepatotoxicity in that context. And that really motivated us to put the publication together to due diligence, and in the publication spend a lot of time to kind of outline each patient case in detail around metrics surrounding time from last immune therapy, the number of days on sotorasib, the best response to sotorasib, the interval between sotorasib and adagrasib, the duration of adagrasib and then the grade of hepatotoxicity seen in each of the contexts, and particularly kind of the adagrasib and patient disease status as well. We were quite inspired by the effort to try to, if we do not have randomized data in comparison of one medicine to another, which we do not at this juncture, we do not have a randomized analysis to really diligently and rigorously compare the rates of AEs across each medicine, and even in sequence, we do not have that with immune therapy. But what we felt was trying to get more analysis of this sequential approach of, if patients had received a medicine, had to be taken off because of toxicity and then actually tried on a new medicine, what were those rates? We felt like that was at least some information to try to get at this question. Dr. Rafeh Naqash: And you bring forward a very important point, which is, a lot of times in the real world setting we don't have cross trial comparisons that can be fully applicable, or we don't have trials that compare two drugs of the same class with respect to the AE profile or efficacy. And observations like the one that you described that led to this study are extremely critical in trying to help answer these questions.  From a data standpoint, and you allude to it to some extent in your manuscript, the trials that are trying to address combination of KRAS-G12C with immunotherapy, especially sotorasib or adagrasib, can you elaborate on that data, what has been published so far and summarize it for our listeners? Dr. Hatim Husain: So there is data from clinical trials looking at patients actually who have received concomitant immune therapy and sotorasib. What was seen in this, in a real world analysis, was that some patients actually who had received sotorasib within a close proximity of immune therapy, as well as a larger study actually which showed in combination there were higher rates of hepatotoxicity in that context. In fact, there were rates of grade 3 hepatotoxicity. And I think built upon that data there's a recognition in the field that we have to be very diligent in terms of even the clinical trial designs in how to understand the pairing between immune therapy and selective G12C inhibitors. There are many trials that are ongoing, one of the studies that is ongoing is known as the KRYSTAL-7 study, which is evaluating adagrasib in combination with pembrolizumab in the first line. And we await more information on that strategy as well. In the context of sotorasib, because of some of the trials that have shown higher rates of hepatotoxicity, there are some additional trials now looking at sotorasib in combination with chemotherapy, and those also have some information that have been reported as well. Dr. Rafeh Naqash: From a drug development standpoint, as you mentioned, there's always a tendency to combine something with something else. And in my practice, and I'm sure in your practice too, when we do early phase trials, many trials are still focused on choosing the maximum tolerated dose, which may be something that we need to gradually move away from as we try to implement these combinations of multiple antibodies plus some of these target agents from maybe the biological optimal dose rather than the maximal tolerant dose is a better way to look at the drugs, the pharmacokinetic profile, and then see what is likely the safest combination with the most appropriate target engagement. Do you have any thoughts on that or insights on that from a drug development perspective? Dr. Hatim Husain: It's a wonderful question and I think it is a very insightful question and understanding of where we are in space right now. And I agree with you that historically, cancer drug development was really hinged upon medicines that perhaps required higher doses to see a benefit or to inch out kind of marginal increases upon where we were at. Now, in combination with medicines that have non-overlapping mechanisms of action, the concept is: Can there actually be more synergy across an approach using combinatorial strategies rather than just additive effects? And I think that in some cases this is being studied with immune therapy, in some cases actually even in the context of other novel mechanisms for cancer therapy. I think that in my practice, I will really try to see how a patient at an approved dose will respond. But definitely I'm open to the concept that there may be a dose that doesn't have to be the maximally tolerated dose, but rather the dose that responses can be seen and perhaps actually at a lower dose than what drives many toxicities. Dr. Rafeh Naqash: I often describe this to my patients as individual patient dose optimization outside of a clinical trial, where I'm sure you've probably done this, where in older adults maybe a lower dose of osimertinib is tolerated better, or a lower dose of sotorasib or adagrasib for that matter, tolerated better with perhaps a similar level of efficacy, since we don't have comparisons between doses and efficacy so far.  So I think in the bigger picture, as we discussed in a nutshell, what I would really like the listeners to understand is as we try to move towards this field of precision medicine targeting more and more of the undruggable genes, there's bound to be a certain level of toxicity patterns that we'll start observing. So I think these real world scenarios which may not be addressed using clinical trials because it is in the real world setting where you cycle one treatment after another after another, which may or may not be allowed in most trials and the real world setting can inform, in certain cases, subsequent trial designs. So I think the most important message, at least that I took from your manuscript, was that these real world observations can make a huge difference and inform practice, even though the data sets may be small. Of course, you want to validate some of these findings in a bigger, broader setting, but proof of concept is there. And I think next time I see an individual in my clinic where I see better toxicity, I'll definitely try to talk to them about subsequent treatment with another KRAS inhibitor, maybe adagrasib or something else, if and when appropriate.  Do you have any closing thoughts on some of these things that we discussed? Dr. Hatim Husain: I just want to leave the audience actually with this concept that sometimes we group targeted therapy side effects as being class effects unanimously. And I do think actually that each inhibitor may have different off target effects on where medicine may act. We don't truly understand the mechanism of hepatotoxicity in the context of selective KRAS-G12C inhibitors. One of the hypotheses may be due to off target cysteine reactivity in the numerous off target binding sites that certain medicines may have over others. And just even qualitatively which off target binding sites there may be, and how that may lead to either immunogenic responses and other organs or such. So I do think that we do need more research to understand the mechanism. But I think where we are at right now in this space is not assuming that all medicines are going to have the exact same toxicity. I think especially when patients may not have other options, this is something to consider as well. Dr. Rafeh Naqash: Thank you so much. Now, outside of the scientific insights, Hatim, I know you a little bit from before. And knowing the kind of work that you've done in precision medicine, I'm really interested to know about where you started, how you started, how things have been, and what kind of advice you have for junior faculty fellows who are interested in this field of precision medicine that is becoming more and more exciting as we progress in the oncology space. Dr. Hatim Husain: Thank you, Rafeh. I will say, actually as a medical student, I was actually very interested in oncology, partly because it was then and still remains one disease or a constellation of diseases that just has such a high psychological burden on patients. And through the experiences I've had, I really can understand and relate with that concept. I did my medical school at Northwestern, residency at the University of Southern California, and then my oncology fellowship at Johns Hopkins University.  And now I've been on faculty at University of California, San Diego, for about 12 years now. It's been a great experience paralleled with the fact that during these last 12 years, I've really seen how the developments in precision oncology, both targeted therapy as well as immune therapy, have really blossomed and unfolded. A large area of my research in my career has kind of focused on cancer genome and integration of novel technologies to really see how they may have clinical application. When I was in my fellowship and as a young faculty, the liquid biopsy was actually coming into development. And this was hinged upon information that had come forward in the prenatal space where some patients actually who were undergoing prenatal testing during pregnancy were found to have complex karyotypes and genomic alterations and then retrospectively found to have cancer.  And doing my fellowship at Johns Hopkins, some of the pioneers in liquid biopsy were my mentors and really kind of instilled in me that passion for really thinking through how cancer genomics can be integrated through time. And some of the research that I have been doing has been looking at clonal evolution of cancer, how cancer is changing over time, and how we can think through the right surveillance strategies to really understand how that change is occurring. The dynamics of ctDNA in retrospective cohorts have been studied and shown that, you know, there can be associations between progression-free survival and other clinical endpoints. The current paper that we are speaking about parallels that in a certain way where, rather than say, looking at clonal evolution and say, the efficacy answer of sotorasib first and then adagrasib and how frequently can adagrasib salvage patients, this looks at it from a different angle around toxicity. And I think that is a key point because, at my core, I really do enjoy the clinical aspect of complex decision making on behalf of patients weighing efficacy and toxicity that they may have as they try to get the best quality of life through this journey. Dr. Rafeh Naqash: Thank you again, Hatim, for all those insights, both from the scientific perspective as well as personal perspective. We appreciate that you chose JCOPO as the destination for your work.  And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Hatem Husain Disclosures Consulting or Advisory Role: AstraZeneca, Foundation Medicine, Janssen, NeoGenomics Laboratories, Mirati Speakers' Bureau: AstraZeneca, Janssen Institution Research Funding: Pfizer, Bristol-Myers Squibb, Regeneron, Lilly Travel, Accommodations, Expenses: AstraZeneca, Janssen, Foundation Medicine  

La cafeína es considerada una droga psicoactiva por varias organizaciones debido a sus efectos estimulantes en el sistema nervioso central. Algunas de las principales entidades que clasifican a la cafeína como una droga son:1.Organización Mundial de la Salud (OMS) – Considera la cafeína una sustancia psicoactiva y ha estudiado su potencial adictivo en diversos informes. 2.Administración de Alimentos y Medicamentos de EE. UU. (FDA) – Clasifica la cafeína como un fármaco y un aditivo alimentario. 3.Instituto Nacional sobre el Abuso de Drogas (NIDA, EE. UU.) – La incluye en la categoría de sustancias psicoactivas con potencial de abuso leve. 4.Asociación Americana de Psiquiatría (APA) – En el DSM-5 (Manual Diagnóstico y Estadístico de los Trastornos Mentales), reconoce la “intoxicación por cafeína” y el “síndrome de abstinencia de cafeína” como trastornos médicos. 5.Organización Internacional del Café (ICO) – Aunque no la clasifica como droga, reconoce sus efectos psicoactivos y el potencial de dependencia. 6.Comité Olímpico Internacional (COI) y Agencia Mundial Antidopaje (AMA) – Hasta 2004, la cafeína estaba en la lista de sustancias prohibidas en el deporte; aunque ya no lo está, sigue siendo monitoreada por sus efectos estimulantes.Aunque la cafeína es legal y de consumo generalizado, su clasificación como droga psicoactiva se debe a su capacidad para afectar el cerebro y generar dependencia.1: Genera adicción y dependencia extrema2: Dependería de una sustancia para hacer mi vida3: Altera los patrones de sueño4: Gastaría dinero todos los días de forma innecesaria5: Muchos cafés (como el torrefacto o las cápsulas de máquina) contienen sustancias cancerígenas y además el café provoca estrés, ansiedad, problemas de corazón y del estómago. Y mancha los dientes.6: Pierdo libertad y foco (después de sus efectos)7: Impacto medio ambiental desmesurado de los monocultivos del café que acaban con la biodiversidad de toda la zona de plantación.Todo esto no me lo he inventado yo. Hay infinidad de estudios científicos que dejo en la descripción.No hace falta ser Albert Einstein para tomar un café y activarte al momento y para darse cuenta de la adicción que genera. Siempre cuento que el médico le dijo a mi madre que dejará el café y el tabaco. El tabaco lo dejó al momento, el café lo redujo pero nunca lo dejó.Aquí tienes la lista ordenada de alimentos y bebidas con más cantidad de cafeína: 1.5-hour Energy (shot energético) – 350 mg/100 ml 2.Café espresso – 212 mg/100 ml 3.Tabletas de cafeína (por unidad) – 100-200 mg 4.Café de prensa francesa – 120 mg/100 ml 5.Café de filtro – 96 mg/100 ml 6.Bang Energy – 63 mg/100 ml 7.Redline Xtreme – 64 mg/100 ml 8.Café instantáneo – 63 mg/100 ml 9.Chocolate negro (>85% cacao, por 100 g) – 80 mg 10.Semillas de guaraná (por gramo) – 40-80 mg 11.Chicles con cafeína (marca especial, por unidad) – 50-100 mg 12.Monster Energy – 32 mg/100 ml 13.Red Bull – 32 mg/100 ml 14.Rockstar Energy – 31 mg/100 ml 15.Té negro – 47 mg/100 ml 16.Té matcha (preparado) – 25-35 mg/100 ml 17.Helado de café (por ración de 100 g) – 30-45 mg 18.Té verde – 30 mg/100 ml 19.Refrescos de cola – 10 mg/100 ml 20.Agua con cafeína (marcas especiales) – 10-50 mg/100 ml 21.Chocolate con leche (por 100 g) – 20 mg 22.Café descafeinado (contiene algo de cafeína) – 2 mg/100 ml Vamos con algunos estudios científicos que dicen que el café es bueno:Estudios científicos que dicen que tomar hasta 4 tazas de café es bueno para el corazón, vivir más y cosas así.Es curioso como existen infinidad de estudios científicos que te dejo en la descripción que indican que la cafeína es una droga con efectos secundarios gravísimos pero el café que es la bebida con más cantidad de cafeína de repente es bueno.Ok, debes saber esto: Nestlé, la marca de cereales azucarados que conoces y del chocolate Nestlé, es la propietaria de Nescafé. Mira: Desde 1963 existe el Organización Internacional del Café que busca aumentar el consumos del café en el mundo.El Promotion Fund del International Coffee Agreement (ICA) fue creado en 1968 como parte de los esfuerzos de la Organización Internacional del Café (OIC) para promover el consumo de café a nivel mundial. Su objetivo principal era financiar campañas de marketing, investigaciones y actividades para aumentar la demanda de café, especialmente en mercados emergentes.¿Sabes quién está ahí metido? Nestlé.El de los cereales que junto a Coca-Cola y Pepsi financian diversos estudios científicos para echar la culpa al sedentarismo y a las grasas del cáncer, ataques al corazón, diabetes… y no al verdadero culpable, el azúcar.Mira: https://borjagiron.com/estudios-cientificos-financiados-coca-cola-pepsi/Nestlé, a través de su marca Nescafé, ha invertido en programas de desarrollo y sostenibilidad del café, como el Nescafé Plan, que busca mejorar la calidad del café, apoyar a los agricultores y fomentar el consumo global.Nestlé tiene Alianza Estratégica con Starbucks desde 2018:* para expandir globalmente las marcas Starbucks® en el sector de foodservice. En este marco, Nestlé se convirtió en distribuidor autorizado de productos Starbucks® en canales fuera del hogar. weproudlyservestarbucks.com* Estudio sobre el Café y la Diabetes Tipo 2 (2013): Científicos de Nestlé, en colaboración con el Hospital Universitario de Lausanne y la Universidad de Berna, publicaron un estudio en el American Journal of Clinical Nutrition que demostró que el consumo de café soluble puede reducir la resistencia a la insulina, un factor subyacente en la diabetes tipo 2 y enfermedades cardiovasculares. 
empresa.nestle.es
* Uso de Inteligencia Artificial en el Cultivo de Café (2024): Nestlé ha empleado inteligencia artificial para desarrollar variedades de café más resistentes al cambio climático. Un hito clave de este proyecto fue la creación de un genoma de referencia de alta calidad para el café arábica, facilitando el desarrollo de cultivos más resilientes. 
hostelvending.com
¿Todo eso funciona? Aumento de las ventas año tras año.En 2023 el mercado del café estaba valorado en aproximadamente 495 mil millones de dólares y se espera que siga creciendo en los próximos años.Se consumen más de 2,25 mil millones de tazas de café al día.La cafeína es una droga. El café es la bebida con más concentración de cafeína. Y de repente el café es bueno.Es como el vino. Los estudios se hacen con vino sin alcohol pero eso no se dice. En marketing radical se enfatiza lo positivo. Yo solo bebo agua, agua con gas y limón.No bebo refrescos, alcohol, ni té ni café.Estudios científicos usados:Caffeine, coffee, and healthS. Garattini Published 1993 MedicineCaffeine: sleep and daytime sleepiness.Published 1 abr 2008 · T. Roehrs, T. RothCaffeine addiction: Need for awareness and research and regulatory measures.Published 4 feb 2017 · Shobhita Jain, A. S. Srivastava, R. Verma, Gaurav MagguRational Addiction to Caffeine: An Analysis of Coffee ConsumptionPublished 1 oct 1996 · N. Olekalns, P. BardsleyCaffeine – An Invisible AddictionPublished 11 jun 2023 · Sidra Ajmal, Laiba Ajmal, Aleena Babar, Amna Riasat, Farhat Batool, Tehniyat ZafarAddiction of Caffeine and SugarPublished 29 jun 2020 · P. CusackA Literature Review on Caffeine Related Disorder in Line with Coffee AddictionPublished 24 ene 2022 · Literature Review, Patrizia Muradi, A. ÜnalMás estudios en Instagram.com/borjagiron y en https://www.linkedin.com/feed/update/urn:li:activity:7290334638009376768/Comparte el episodio si crees que puede ayudar a alguien. Suscríbete para no perderte el resto de episodios.Conviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/los-ultimos-dias--2659766/support.

In this episode of the PFC Podcast, Dennis and John discuss the ongoing updates and changes within the Tactical Combat Casualty Care (TCCC) guidelines. They delve into the role of the TTC Committee, the importance of literature reviews in developing algorithms for trauma care, and the proposed changes to the March algorithm, emphasizing the need for resuscitation before decompression. The conversation also covers the overhaul of the analgesic section, the recommendations for antibiotics, and the role of TXA in treating hemorrhagic shock. Additionally, they touch on the significance of triage in mass casualty situations and the future directions of the committee's work. Takeaways TCCC is continuously updated to reflect new research. Resuscitation should be prioritized over decompression in trauma care. The March algorithm may undergo significant changes to improve outcomes. Analgesic options are being re-evaluated due to supply issues. Rocephin is being recommended as a primary antibiotic. TXA is crucial for managing hemorrhagic shock in trauma patients. Triage protocols are essential for effective mass casualty management. The committee is open to innovative ideas and solutions. Training and education are vital for implementing new guidelines. Future meetings will focus on finalizing and voting on proposed changes. Chapters 00:00 Introduction to the PFC Podcast 02:46 Understanding the TTC Committee and Its Role 06:06 Literature Review and Algorithm Development 09:00 Resuscitation vs. Decompression in Trauma Care 12:07 Proposed Changes to the March Algorithm 15:06 Analgesic Section Overhaul and Alternatives 18:09 Antibiotic Recommendations and Changes 20:54 TXA and Its Role in Hemorrhagic Shock 23:51 Triage in Mass Casualty Situations 26:45 Future Directions and Upcoming Votes 30:06 Conclusion and Final Thoughts Thank you to Delta Development Team for in part, sponsoring this podcast. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠deltadevteam.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ For more content go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠ Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care

No episódio de hoje recebemos a Dra. Dayane Issaho, oftalmopediatra e especialista em estrabismo pela UNIFESP e UT Southwestern (Dallas, EUA). Com doutorado e pós-doutorado em Oftalmologia pela UNIFESP e atual presidente do Centro Brasileiro de Estrabismo (CBE), a Dra. Dayane compartilha sua ampla experiência em um bate-papo cheio de informações valiosas.Conversamos sobre como realizar o exame oftalmológico infantil, as diferenças entre pseudoestrabismo e estrabismo, os desvios oculares mais comuns no primeiro ano de vida e os principais sinais de alerta que devem ser observardos. Além disso, exploramos a abordagem e o manejo de condições como esotropia acomodativa e exotropia intermitente.Este episódio está imperdível!MATERIAL SUPLEMENTAREstudos:BifocaisCan J Ophthalmol. 1984 Aug;19(5):220-3. Sensory outcome with nonsurgical management of esotropia with convergence excess (a high accommodative convergence/accommodation ratio) J A Pratt-Johnson, G Tillson (https://pubmed.ncbi.nlm.nih.gov/6478307/)JAAPOS. 1985 Nov-Dec;22(6):238-42. doi: 10.3928/0191-3913-19851101-09. The management of esotropia with high AC/A ratio (convergence excess) J A Pratt-Johnson, G Tillson (The management of esotropia with high AC/A ratio (convergence excess) - PubMed)Manejo da Exotropia IntermitenteArq Bras Oftalmol, 2022. Management of Intermittent exotropia in childhood: current concepts of the literature and the experts. Hopker LM (https://www.scielo.br/j/abo/a/stNgM3n3dRMwK5n9FttscZh/). Lentes Negativas (overminus) para exotropia intermitenteJ Current Ophthalmol 2020. Non-Surgical Management Options of Intermittent Exotropia. A Literature Review. Samira H. (https://journals.lww.com/joco/fulltext/2020/32030/non_surgical_management_options_of_intermittent.1.aspx)Strabismus 2024. Divergence excess and basic exotropia types of intermittent exotropia: a major review. Part 2: non-surgical and surgical treatment options. (https://www.tandfonline.com/doi/full/10.1080/09273972.2023.2291056.JAMA 2021. Overminus Lens Therapy for Children 3 to 10 Years of Age With Intermittent Exotropia. A Randomized Clinical TrialLentes Negativas (overminus) x indução de miopiaArch Ophthalmol. 1999. Does overcorrecting minus lens therapy for intermittent exotropia cause myopia? Kushner B (https://pubmed.ncbi.nlm.nih.gov/10326961/)BJO 2022. Comparison of biometric and refractive changes in intermittent exotropia with and without overminus lens therapy. Magar JBA. (https://bjo.bmj.com/content/107/10/1526)JAMA 2021. Overminus Lens Therapy for Children 3 to 10 Years of Age With Intermittent Exotropia A Randomized Clinical Trial. Chen AM (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2777181)

What happens when you need to find the reliability of something ... but don't have a lot of data or information in your organization about it? Well ... there is a fair bit of information out there, if you know where to look. But be careful! There's a lot of disinformation as well. So what can you do? The post SOR 1032 Available Reliability Information appeared first on Accendo Reliability.

Send us a textIn today's DigiPath Digest, we delve into federated learning, a decentralized approach to AI training that preserves data privacy. I discuss recent papers from PubMed and share my experiences experimenting with AI tools like Perplexity and Gemini for research efficiency. You will also get updates on upcoming plans, including leveraging AI to share more podcasts with you. Did I mention that this is the last livestream of the year as I head to Poland for Christmas? No More DigiPath Digests. We got to number 18 (I overestimated it a bit in the podcast), and you have been instrumental in continuing this series!Big THANK YOU to all the digital Pathology #TRLBLZRS showing up every Friday morning for this!Join me as we tackle the nuances of federated learning and its impact on healthcare and pathology.00:00 Introduction and Greetings00:18 Today's Topic: Federated Learning00:57 AI Tools and Updates04:39 Federated Learning in Detail08:03 Challenges and Benefits of Federated Learning11:21 Exploring More Papers and Future Plans22:53 Wrapping Up and Final ThoughtsLinks and Resources:Subscribe to Digital Pathology Podcast on YouTubeFree E-book "Pathology 101"YouTube (unedited) version of this episodeTry Perplexity with my referral linkMy new page built with PerplexityPublications Discussed Today:

Episode 6 of Student Special Needs Advanced Mentoring Master Classes, from the Office of Research and Doctoral Services at Walden University with host, Dr. Lee Stadtlander. In this session Drs. Stadtlander, Kelly Chermack, Nicole Hamilton, Corrine Bridges discuss Working with Students on the Literature Review.

HEALTH NEWS   Why Raspberries Are the New Heart-Healthy Superfruit Effects of Ashwagandha (Withania Somnifera) on Stress and Anxiety: A Systematic Review and Meta-analysis Magnetic stimulation effective in helping Parkinson's patients walk Vitamin E deficiency may lead to increased colorectal cancer risk: Chinese meta-analysis Exposure to phthalates could be linked to pregnancy loss  Children who claim previous life memories: A Case Report and Literature Review

Send us a textIn this episode of DigiPath Digest, we review the latest AI developments in digital pathology described in the literature. I explore how AI is pushing the boundaries of metastasis detection, breast cancer treatment predictions, lung cancer research trends, and the creation of pathology foundation models. Episode Breakdown:00:00 – Welcome & Introduction00:36 – Sentinel Node Metastasis Detection: A discussion on the development of an AI model that can detect sentinel node metastasis in melanoma with accuracy comparable to that of pathologists. The model aids in distinguishing between nodal metastasis and intra-nodal nevus, which is crucial for accurate staging in melanoma patients.05:01 – Predicting Breast Cancer Treatment Response: A cross-modal AI model that integrates pathology images and ultrasound data is explored. This model is designed to predict a breast cancer patient's response to neoadjuvant chemotherapy, providing personalized insights that can guide treatment decisions.09:59 – Global Trends in AI and Lung Cancer Pathology: This section reviews a bibliometric study that analyzed global research trends in AI-based digital pathology for lung cancer over the past two decades. The study highlights the need for increased collaboration between institutions and countries to further AI advancements in this area.13:30 – Pathology Foundation Models: An in-depth look at a new foundation model in pathology, designed to generalize across various diagnostic tasks. This model shows significant promise in cancer diagnosis and prognosis prediction, outperforming traditional deep learning methods by addressing domain shifts across different datasets.20:08 – Domain Shifts in AI Models: A brief discussion on the impact of domain shifts, such as variations in staining protocols and patient populations, on the performance of AI models in pathology. Strategies for mitigating these challenges are highlighted.29:09 – Faster Annotation in Pathology: The episode concludes with a review of a study comparing manual and semi-automated annotation methods. The semi-automated approach significantly reduces the time required for annotating whole slide images, offering a more efficient solution for pathologists.Resources Mentioned:

Send us a textWelcome to the 10th edition of the DigiPath Digest. Today, we discuss essential updates including the free availability of my 'Digital Pathology 101' book and the podcast now accessible on YouTube and YouTube Music. We dive deep into the weekly abstract, focusing on advancements such as sex-specific histopathological models for gliomas, leukocyte identification tools, and automated Gleason grading for prostate cancer. We also explore the potential of SciSpace, an AI tool for interacting with scientific papers. Interspersed with live interaction, we discuss the importance of consistency in histopathological grading and the challenges faced by pathologists. J00:00 Introduction and Announcements00:55 Live Interaction and Updates05:01 Abstract Review: High-Grade Gliomas11:45 Abstract Review: Leukocyte Identification Tool13:24 Abstract Review: Gleason Grading in Prostate Cancer16:31 Abstract Review: HER2 Low Prediction in Breast Cancer24:01 Event Announcements and Closing RemarksTHIS EPISODES RESOURCES:

Send us a Text Message.DigiPath Digest #5 is ready as audio!We explore how AI and image datasets can accelerate medical education for both radiology and pathology. I review comparisons between the GPT-4 vision model and convolutional neural networks for neuropathological changes in the brain. We  explore how AI can potentially reduce healthcare costs, particularly in cancer risk discrimination. Additionally, there's a focus on AI applications in digital urine cytology for bladder cancer diagnosis. I also share personal updates, upcoming podcast guests, and my plans for utilizing YouTube content to create an educational course. The episode wraps up with a lively discussion on integrating AI in clinical workflows and prioritizing patient care.TIMESTAMPS:00:00 Introduction and Podcast Updates03:41 Guest Highlights and Personal Updates06:33 Digital Self-Learning in Radiology12:14 AI in Breast Cancer Risk Assessment18:36 Comparing GPT-4 Vision and CNN in Neuropathology21:58 Challenges in Lesion Identification22:59 Few-Shot Learning in Neuropathology24:42 AI in Bladder Cancer Diagnosis29:48 Innovations in Digital Pathology38:48 AI-Powered Clinical Workflows44:42 Conclusion and Future DirectionsTODAY'S ABSTRACTS & RESOURCES:Improving the diagnostic performance of inexperienced readers for thyroid nodules through digital self-learning and artificial intelligence assistanceU.S. payer budget impact of using an AI-augmented cancer risk discrimination digital histopathology platform to identify high-risk of recurrence in women with early-stage invasive breast cancerEvaluating the efficacy of few-shot learning for GPT-4Vision in neurodegenerative disease histopathology: A comparative analysis with convolutional neural network modelEvaluating artificial intelligence-enhanced digital urine cytology for bladder cancer diagnosisSupport the Show.Become a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Reading If you want to spend any amount of time with your child beyond hugs, feeding and basic life duties, I would recommend reading above all else. I find it hard to believe that this is the first article that I have written on reading. I pondered that for a minute and concluded that this, in effect, was me taking this information for granted. That ends today. When I reflect on my journey on the road to reading literacy, I note that I was not an avid reader. Nay, I hated reading for most of my childhood. My first self chosen pleasure book was The Firm when I was 23 years old. Why would this be? To sit for me was and is akin to mild torture. While other kids loved to dive into a book, that was not for me. Run, play, drum, hike, yes sir. All in....plus a Literature Review and section on Memorial Day. Enjoy, Dr. M

Ian Mark (@iantmark) joins Dr. Vilanilam as this month's guest. They discuss Dr. Mark's article, "7T MRI for Cushing Disease: A Single-Institution Experience and Literature Review," from the July issue of AJNR. (16:36)

In episode 409 of The Brainy Business podcast, Haley Swafford, Market Research Manager at Microsoft, shares her insights into emotional brand relationships and the effort to drive love for the Microsoft brand. Haley's extensive background in market research, coupled with her passion for uncovering emotionally centered insights, shines through as she discusses the pivotal combination of functional and emotional components in understanding brand-customer relationships. Her emphasis on the significance of love as a focus for Microsoft, in contrast to traditional themes of innovation and empowerment, offers a fresh perspective on building emotional connections with the brand.  Haley's in-depth explanation of the research process and the subsequent decision to prioritize love as a descriptor for brand relationships provides a compelling reason for brand managers and marketers to tune in to this episode. Her practical insights, including the need to make research findings actionable and contextualize research learnings within the brand love model, offer actionable takeaways for businesses seeking to enhance their emotional relationships with customers. This episode provides a unique opportunity to gain valuable insights and strategies for fostering emotional brand connections. In this episode: Uncover the secrets to building strong emotional connections with your brand and customers. Explore Microsoft's groundbreaking approach to cultivating brand love and loyalty. Discover the profound impact of emotionality on consumer decision-making and brand preference. Master the techniques for accurately measuring and analyzing the emotional resonance of your brand. Harness the power of AI to revolutionize and optimize your market research strategies. Show Notes: 00:00:00 - Introduction Melina introduces Haley Swafford and highlights her passion for uncovering emotionally centered insights to diversify and strengthen traditional research approaches. 00:06:07 - The Journey to Prioritizing Microsoft Love Haley shares the journey of prioritizing Microsoft Love, starting with the discrepancy between the company's revenue and brand value. This led to the creation of her role and a focus on understanding emotionality for the brand. 00:10:40 - Understanding Emotionality in Brand Relationships Haley explains emotionality as the combination of functional and emotional components in human decision-making. She emphasizes the importance of driving positive, memorable, and influential brand memories to shape the brand's relationship with its customers. 00:13:34 - Can You Love a Brand? The Microsoft Challenge Haley discusses the audience's response to the question of loving a brand, particularly a technology brand like Microsoft. The data reflected a neutrality problem, prompting the need to drive a more emotional relationship with the brand. 00:14:59 - Settling on "Love" as the Brand Emotion Haley shares the research process that led to the decision to focus on "love" as the brand emotion. Despite other contenders like innovation and empowerment, love emerged as the strongest model and a renewed focus for Microsoft's brand strategy. 00:17:16 - The Concept of Brand Love Haley discusses the two key aspects of brand love: identity and trust. She explains how people see themselves in a brand and the importance of building a brand that represents and supports them. 00:19:23 - Literature Review and Research Process Haley shares her approach to conducting qualitative and quantitative research and the extensive literature review she did. She emphasizes the importance of clear objectives and communication to successfully pitch a project. 00:26:02 - Emotional Inquiry and Research Findings Haley talks about the emotional inquiry technique used by the research partner, Brand Trust, to gather memorable brand experiences. She highlights the process of organizing the research findings and anchoring them to the brand love model. 00:29:34 - Commercial Audience Research Haley explains the challenges and rewards of conducting research with commercial audiences. She emphasizes the importance of bringing colleagues along on the research journey and the significance of understanding differences by products and audiences. 00:33:07 - Actionable Insights from Research Haley delves into the actionable insights derived from the research, focusing on the components of the brand love model. She highlights the importance of making love a part of everyday work and aligning it with business goals. 00:35:54 - Framing Learnings to Drive Love Haley emphasizes the importance of framing learnings to drive love as a source of truth and the need for sheer repetition for people to remember and implement the insights. Workshops with external partners have been helpful in deeply understanding driving love for the business. 00:37:53 - Emphasizing Actionability and Scalability Haley discusses the need for scalability in driving love at Microsoft and the support from the new CMO in emphasizing the priority of driving love in the context of AI. Actionable projects include workshops and generating emotive copy using emotionality learnings. 00:38:38 - Exciting Future Projects Haley shares her excitement about learning more about integrating love into the business, such as formalizing the intake process, prompt engineering using emotionality learnings, and creating a tactical step-by-step concept for business goals. 00:40:42 - Conclusion What stuck with you while listening to the episode? What are you going to try? Come share it with Melina on social media -- you'll find her as @thebrainybiz everywhere and as Melina Palmer on LinkedIn. Thanks for listening. Don't forget to subscribe on Apple Podcasts or Android. If you like what you heard, please leave a review on iTunes and share what you liked about the show.  I hope you love everything recommended via The Brainy Business! Everything was independently reviewed and selected by me, Melina Palmer. So you know, as an Amazon Associate I earn from qualifying purchases. That means if you decide to shop from the links on this page (via Amazon or others), The Brainy Business may collect a share of sales or other compensation. Let's connect: Melina@TheBrainyBusiness.com The Brainy Business® on Facebook The Brainy Business on Twitter The Brainy Business on Instagram The Brainy Business on LinkedIn Melina on LinkedIn The Brainy Business on Youtube Connect with Haley: Haley on LinkedIn Learn and Support The Brainy Business: Check out and get your copies of Melina's Books.  Get the Books Mentioned on (or related to) this Episode: Playing with Reality, by Kelly Clancy Blindsight, by Matt Johnson and Prince Ghuman Neurobranding, by Peter Steidl What Your Customer Wants and Can't Tell You, by Melina Palmer The Power of Us, by Jay Van Bavel & Dominic Packer Top Recommended Next Episode: Memory Biases (ep 280) Already Heard That One? Try These:  Sarah Thompson Interview (ep 259) Dominic Packer Interview (ep 304) Prince Ghuman Interview (ep 344) Kelly Clancy Interview (ep 403) Peak-End Rule (ep 408) Other Important Links:  Brainy Bites - Melina's LinkedIn Newsletter

Many people think of summer as the best time to read. On the beach, on the airplane to a vacation, in between semesters… Sounds like a perfect time to do a literature review. But there are many ways to do a literature review, and in all honesty, we think most people choose the wrong type of review – the “systematic” literature review where they select papers about a phenomenon, do a supposedly structured but not exhaustive search across IS journals, and then criticize the knowledge others have created. We discuss a few alternatives that we think hold more promise: qualitative and quantitative meta analyses, or narrative and integrative reviews. We also point to a few papers that have helped us organize the conversations we read about in the literature – which really, is what literature reviewing is all about.  References Berente, N., Lyytinen, K., Yoo, Y., & Maurer, C. (2019). Institutional Logics and Pluralistic Responses to Enterprise System Implementation: A Qualitative Meta-Analysis. MIS Quarterly, 43(3), 873-902. Noblit, G. W., & Hare, R. D. (1988). Meta-Ethnography: Synthesising Qualitative Studies. Sage. King, W. R., & He, J. (2006). A Meta-analysis of the Technology Acceptance Model. Information & Management, 43(6), 740-755. Zaza, S., Joseph, D., & Armstrong, D. J. (2023). Are IT Professionals Unique? A Second-Order Meta-Analytic Comparison of Turnover Intentions Across Occupations. MIS Quarterly, 47(3), 1213-1238. Trang, S., Kraemer, T., Trenz, M., & Weiger, W. H. (2024). Deeper Down the Rabbit Hole: How Technology Conspiracy Beliefs Emerge and Foster a Conspiracy Mindset. Information Systems Research, . Berente, N., Salge, C. A. D. L., Mallampalli, V. K. T., & Park, K. (2022). Rethinking Project Escalation: An Institutional Perspective on the Persistence of Failing Large-Scale Information System Projects. Journal of Management Information Systems, 39(3), 640-672. Skinner, R. J., Nelson, R. R., & Chin, W. (2022). Synthesizing Qualitative Evidence: A Roadmap for Information Systems Research. Journal of the Association for Information Systems, 23(3), 639-677. vom Brocke, J., Simons, A., Niehaves, B., Riemer, K., Plattfault, R., & Cleven, A. (2009). Reconstructing the Giant: On the Importance of Rigour in Documenting the Literature Search Process. 17th European Conference on Information Systems, Verona, Italy. vom Brocke, J., Simons, A., Riemer, K., Niehaves, B., Plattfault, R., & Cleven, A. (2015). Standing on the Shoulders of Giants: Challenges and Recommendations of Literature Search in Information Systems Research. Communications of the Association for Information Systems, 37(9), 205-224. Bunge, M. A. (1977). Treatise on Basic Philosophy Volume 3: Ontology I - The Furniture of the World. Kluwer Academic Publishers. Burton-Jones, A., Recker, J., Indulska, M., Green, P., & Weber, R. (2017). Assessing Representation Theory with a Framework for Pursuing Success and Failure. MIS Quarterly, 41(4), 1307-1333. Recker, J., Indulska, M., Green, P., Burton-Jones, A., & Weber, R. (2019). Information Systems as Representations: A Review of the Theory and Evidence. Journal of the Association for Information Systems, 20(6), 735-786. Saghafi, A., & Wand, Y. (2020). A Meta-Analysis of Ontological Guidance and Users' Understanding of Conceptual Models. Journal of Database Management, 31(4), 46-68. Leonardi, P. M., & Vaast, E. (2017). Social Media and their Affordances for Organizing: A Review and Agenda for Research. Academy of Management Annals, 11(1), 150-188. Orlikowski, W. J., & Scott, S. V. (2008). Sociomateriality: Challenging the Separation of Technology, Work and Organization. Academy of Management Annals, 2(1), 433-474. Felin, T., Foss, N. J., & Ployhart, R. E. (2015). The Microfoundations Movement in Strategy and Organization Theory. Academy of Management Annals, 9(1), 575-632. Cronin, M. A., & George, E. (2023). The Why and How of the Integrative Review. Organizational Research Methods, 26(1), 168-192. Paré, G., Trudel, M.-C., Jaana, M., & Kitsiou, S. (2015). Synthesizing Information Systems Knowledge: A Typology of Literature Reviews. Information & Management, 52(2), 183-199. Rivard, S. (2014). Editor's Comments: The Ions of Theory Construction. MIS Quarterly, 32(2), iii-xiii. Leidner, D., Berente, N., & Recker, J. (2023). What's been done, what's been found, and what it means. This IS research podcast, . Webster, J., & Watson, R. T. (2002). Analyzing the Past to Prepare for the Future:  Writing a Literature Review. MIS Quarterly, 26(2), xiii-xxiii. Grisot, M., & Modol, J. R. (2024). Special Section Introduction: Reflecting and Celebrating Ole Hanseth's Contribution to the IS Community. Scandinavian Journal of Information Systems, 36(1), 39-40. Association for Information Systems (2023. History of AIS. .

Send us a Text Message.This is the audio version of the DigiPath Digest - Abstract review that I host on YouTubeHere is the video version if you learn more visuallyToday I explain what happened with my "beginning of year initiative" to post an audio version of the Digital Pathology Newsletter sent out in an email form. In a nutshell: I just stopped posting it, you will find out why in this episode.TIMESTAMPS00:00 Introduction to DigiPath Digest00:13 Challenges in Digital Pathology01:31 Consistency and Sustainability02:51 Abstract Review Process04:25 Engaging with the Community08:31 First Abstract: Molecular Classification of Breast Cancer14:21 Second Abstract: AI in Breast Cancer Detection20:53 AI-Assisted Pathology: Time Reduction and Sensitivity Improvement21:36 Environmental Impact of Digital Pathology22:23 Technical Difficulties and Viewer Interaction24:30 French Authorities on Digital Pathology's Environmental Cost28:45 Cephalometric Analysis: Digital vs. Manual Tracing31:46 Exploring Undermined.ai for Scientific Research43:05 Concluding Remarks and Future PlansTODAY'S ABSTRACTS & RESOURCESMolecular Classification of Breast Cancer Using Weakly Supervised Learning (https://pubmed.ncbi.nlm.nih.gov/38938010/)Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial (https://pubmed.ncbi.nlm.nih.gov/38937624/)[The environmental impact of digital technology and artificial intelligence, in the time of digital pathology] (https://pubmed.ncbi.nlm.nih.gov/38937204/)Digital versus Manual Tracing in Cephalometric Analysis: A Systematic Review and Meta-Analysis (https://pubmed.ncbi.nlm.nih.gov/38929786/) Support the Show.Become a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

In this episode, we dive into a common challenge faced by doctoral learners: understanding and developing a theoretical framework. Special guest Dr. Azadeh Osanloo discusses the importance yet common misunderstanding of the theoretical framework in research. She shares her perspective on why she felt compelled to co-author the article to aid students and professors alike. She explains that the theoretical framework is essential as it serves as the blueprint for the entire dissertation, guiding the research philosophically, epistemologically, methodologically, and analytically. Osanloo further elaborates on how students can discover and utilize theoretical frameworks to support and structure their research effectively.Dr. Azadeh Osonloo - LinkedIn - https://www.linkedin.com/in/azadeh-o-b73189b/ Music by moodmode from PixabaySubscribe & Follow the Show:Linkedin: https://www.linkedin.com/in/denisenixon/Website: https://www.denisenixon.com

RIVER OF GRASS is now streaming on MUBI in the US. Get a whole month of great cinema FREE on MUBI: https://mubi.com/horses https://www.patreon.com/HorsesPThttps://www.horses.land Music:A Way of Life - Christoffer Moe DitlevesenAutonomy - Jakob AhlbomDesert after Storm - Johan GlossnerFlowers in the Mirror - Sayuri Hayashi EgnellHolocene - Harbours and OceansBach Cello Suite No. 2 iin D Minor, MWV 1008 II. Allemande - Laura MetcalfNotice - Arden ForestRainfall Come - William ClaesonSea Arc Eight - Franz GordonSleep Well, Sleep Tight - Gabriel LucasTea at Marlowe - Franz GordonThe Crossing of Time - Gavin LukeWenn Wir in Höchsten Noten Sein - TraditionalWhenever You Leave - Anna Landstrom Sources:“A History of Cannibalism”, Nathan Constantine“Unspeakable Rites: Cultural Reticence and the Cannibal Question, Claude Rawson“Review: The Man Eating Myth,” by Ivan Brady“Criminal Cannibalism: An Examination of Patterns and Styles,” Victor G. Petreca, Gary Brucato, Ann W. Burgess, Elisa Dixon“Assessing the Calorific Significance of Episodes of Human Cannibalism in the Palaeolithic,” James Cole“Eating Human Beings,” Mikel Burley“Carib “Cannibalism”: A Study in Anthropological Stereotyping”, Richard B Moore“The Most Influential Text on Cannibalism: An Analysis of William Arens's The Man-Eating Myth,” Tim Seiter“Neanderthal Cannibalism at Moula-Guercy, Aredeche, France,” A Defleur, et al“Placentophagia in humans and nonhuman mammals: causes and consequences,” Mark B Kristal, et al“Consumption of Maternal Placenta in Humans and Nonhuman Mammals: Beneficial and Adverse Effects,” Daniel Mota-Rojas et al“A Literature Review on the Practice of Placentophagia,” Rachel Joseph et al“Cannibalism,” S.H. Posinsky“Thinking about Cannibalism,” Shirley LindenbaumHorses Patreon: https://www.patreon.com/HorsesPTSee omnystudio.com/listener for privacy information.

In this episode, podcast host Denise Nixon shares 5 key strategies to overcome the fears and mindsets of researchers when writing their dissertations. Researchers often get discourages when they encounter obstacles, like busy work schedules and information overload with all of the schoalrly articles and resources they collect during this process. This episode will explore five strategies to get you started and keep you going on your journey to your completed quality dissertation.Music by moodmode from PixabayMusic by moodmode from PixabaySubscribe & Follow the Show:Linkedin: https://www.linkedin.com/in/denisenixon/Website: https://www.denisenixon.com

In this episode of the Thyroid Answers Podcast I review two recent scientific papers on thyroid physiology with Dr. Kelly Halderman. We break down the important points that are made in the paper so you understand how you might be able to apply the findings to your clients or your own health.  The papers discussed on today's podcast: Yamada S, Horiguchi K, Akuzawa M, Sakamaki K, Shimomura Y, Kobayashi I, Andou Y, Yamada M. Seasonal Variation in Thyroid Function in Over 7,000 Healthy Subjects in an Iodine-sufficient Area and Literature Review. J Endocr Soc. 2022 Apr 6;6(6):bvac054. doi: 10.1210/jendso/bvac054. PMID: 35528829; PMCID: PMC9070835. Joe M El-Khoury, Seasonal Variation and Thyroid Function Testing: Source of Misdiagnosis and Levothyroxine Over-Prescription, Clinical Chemistry, Volume 69, Issue 5, May 2023, Pages 537–538, https://doi.org/10.1093/clinchem/hvad017 Dr. Kelly Halderman has a background in functional medicine, earning her medical doctorate (MD) in 2007 & completing a family practice medicine internship with the University of Minnesota in 2009. She is an international educator in the area of integrative and precision health. Dr. Halderman also has a traditional Naturopathic Medical Degree from KCNH. She holds certification in MethylGenetic Nutrition by The Nutrigenetic Research Institute and certification from The American Functional Neurology Institute in Functional Neurology and Neurofeedback. She is an active member of the American Academy of Anti-Aging Medicine, President and founder of The American Association of Nutraceutical Formulators, and a member of the Physicians Committee for Responsible Medicine and Society of Physician Entrepreneurs. Dr. Halderman has a doctorate in clinical nutrition, is also board certified in Clinical Nutrition by the CNCB, has certification in Plant-Based Nutrition from Cornell University, and health coaching certification from the Institute for Integrative Nutrition. She also has comprehensive experience in nutraceutical science & formulation, creating & educating on novel formulations for consumers, practitioners & professional associations such as the NFL Hall of Fame. A former physician turned executive-level biotech expert, she currently serves as Weo's Chief Health Officer. This health-conscious company harnesses the power of diamond electrolysis to augment the most precious molecule on the planet, water.

Bulimia Nervosa explained, including differences between Bulimia and Anorexia, as well as Bulimia symptoms. Also includes Bulimia Nervosa diagnostic criteria and treatment. Consider subscribing on YouTube (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Bulimia Nervosa? 0:42 Bulimia Epidemiology1:21 Bulimia Symptoms3:55 Bulimia Diagnosis (Bulimia Nervosa DSM 5 Criteria)4:54 Bulimia TreatmentReferencesBMJ Best Practice (2023) “Bulimia Nervosa”. Available at https://bestpractice.bmj.com/topics/en-gb/441Di Evelyn Attia, MD, B. Timothy Walsh, MD - MSD Manual Pro (2023) “Bulimia Nervosa”. Available at https://www.msdmanuals.com/it/professionale/disturbi-psichiatrici/disturbi-dell-alimentazione/bulimia-nervosaCynthia M. Bulik, Ph.D. (2012) “The Changing “Weightscape” of Bulimia Nervosa”. Available at https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2012.12010147Blas Garcia Garcia (2018) “Bilateral Parotid Sialadenosis Associated with Long-Standing Bulimia: A Case Report and Literature Review”. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878158/The Bulimia Project “Bulimia Diagnostic Criteria”. Available at https://bulimia.com/bulimia-diagnostic-criteria/Annelies E. van Eeden (2021) “Incidence, prevalence and mortality of anorexia nervosa and bulimia nervosa”. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500372/Guillermo Firman (2020) “Diagnostic Criteria for Bulimia Nervosa (DSM-5)”. Available at https://medicalcriteria.com/web/bulimia/Please remember this podcast and all content from Rhesus Medicine is meant for educational purposes only and should not be used as a guide to diagnose or to treat. Please consult a healthcare professional for medical advice. 

You are called to a code blue on the postnatal ward. A 28 yr old female who is 1 day post a non elective caesarean section has just had a witnessed convulsion lasting 1-2 min. She has now regained consciousness but seems a little confused and is complaining that she "has lost vision in both of her eyes". Her BP is 180/100, and all other vital signs are normal. What is this most likely to be? What is your differential diagnosis (what things do you not want to miss)? What investigations would you like done? This turns out to be an episode of eclampsia and PRES (posterior reversible encephalopathy syndrome). What is PRES? What are it's radiological features and what is the mechanism which leads to this disorder? Join Graeme and I as we discuss this uncommon but fascinating condition. References Gewirtz AN, Gao V, Parauda SC, Robbins MS. Posterior Reversible Encephalopathy Syndrome. Curr Pain Headache Rep. 2021 Feb 25;25(3):19. doi: 10.1007/s11916-020-00932-1. PMID: 33630183; PMCID: PMC7905767. Marcoccia E, Piccioni MG, Schiavi MC, Colagiovanni V, Zannini I, Musella A, Visentin VS, Vena F, Masselli G, Monti M, Perrone G, Panici PB, Brunelli R. Postpartum Posterior Reversible Encephalopathy Syndrome (PRES): Three Case Reports and Literature Review. Case Rep Obstet Gynecol. 2019 Jan 27;2019:9527632. doi: 10.1155/2019/9527632. PMID: 30809401; PMCID: PMC6369475.

In this episode, host Dr. Ashley Agan discusses eustachian tube (ET) dilation with Dr. Dennis Poe, neurotologist and Professor of Otolaryngology at Harvard Medical School. First, the surgeons describe clinically meaningful differences between adult and pediatric ETs. Then, Dr. Poe reviews workup of pediatric ET disorders. Since inflammation accounts for most ET dysfunction, controlling comorbid allergies and/or performing adenoidectomy provides relief to some patients. For patients with continued symptoms, balloon dilation – now approved for children as young as eight years of age– directly counteracts obstructive inflammation in the tube lumen. To conclude, Dr. Poe describes how to select patients for, perform, and avoid complications of balloon dilation. --- CHECK OUT OUR SPONSOR Acclarent AERA Eustachian Tube Balloon Dilation System https://www.jnjmedtech.com/en-US/product/Acclarent-aera-eustachian-tube-balloon-dilation-system --- SHOW NOTES 00:00 - Introduction 04:03 - Understanding Eustachian Tube Anatomy 07:22 - Causes of Eustachian Tube Dysfunction in Children 12:53 - Examination and Diagnosis of Eustachian Tube Dysfunction 19:10 - Treatment Options for Eustachian Tube Dysfunction 27:05 - Avoiding Unpredictable Injury and Scarring During Balloon Dilation 31:51 - Contraindications and Precautions for Balloon Dilation 37:49 - Understanding Risks & Complications of Balloon Dilation 48:34 - Closing Remarks & Future Prospects --- RESOURCES Dr. Dennis Poe's Harvard Profile: https://oto.hms.harvard.edu/people/dennis-poe BackTable ENT Ep. 40 – “Diagnosis & Management of Eustachian Tube Disorders with Dr. Dennis Poe:” https://www.backtable.com/shows/ent/podcasts/40/diagnosis-management-of-eustachian-tube-disorders American Academy of Otolaryngology-Head and Neck Surgery Clinical Practice Guideline: Otitis Media with Effusion (Update): https://www.entnet.org/quality-practice/quality-products/clinical-practice-guidelines/ome/ “Complications of Eustachian Tube Balloon Dilation: Manufacturer and User Facility Device Experience (MAUDE) Database Analysis and Literature Review,” Chisolm, P.F. et al: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10731503/

I've finished my first large research grant! I guess that makes me a 'real' scientist now. Came here today to share some most interesting aspects of this project with you. Not going to bore you all about the wind and fire interaction physics (hey, there is an entire episode 50 devoted to that!), but rather talk about challenges and stuff that perhaps will matter if you would like to engineer a case similar to one we have studied.So in this podcast episode, we will go into:How our framework for wind and fire coupled modelling worked out in practice (read more about the framework here Wind and Fire Coupled Modelling part 1 - Literature Review and here Wind and Fire Coupled Modelling part 2 - Best Practice Guidelines )How we had to go miles to modify the ABL profile so our wind predictions at the location of the fire are spot on A bit on design fire choice, but plenty more in here: 135 - Contemplating a design fire for car parksAnd most importantly, how we handled the mass amount of data generated in 336 CFD simulations within the project. Our unique approach to statistics, indexing and risk.The promised webinars will be uploaded soon, and you will find the link here.Badania przedstawione w odcinku podcastu przeprowadzono w projekcie realizowanym an podstawie umowy UMO-2020/37/B/ST8/03839 do projektu badawczego nr 2020/37/B/ST8/03839 pt. Skutki oddziaływania wiatru na pożary budynków w wieloparametrycznej ocenie ryzyka z wykorzystaniem metod numerycznych.Grafika autorstwa P. Jamińska-Gadomska (ITB) oraz P. Prusiński (NCBJ) w ramach współracy pomiedzy ITB a NCBJ w projekcie EuroCC (No 951732)

Wondering what the thyroid levels from your thyroid lab test mean? I'll break down what the different thyroid hormones indicate and dispel some misconceptions about which levels actually require medication.  If you have any additional questions you would like answered in the future, let me know in the comments! Watch/Read Next… Optimal Thyroid Levels: https://drruscio.com/optimal-thyroid-levels  Hyperthyroidism vs Hypothyroidism: https://drruscio.com/hyperthyroidism-vs-hypothyroidism/  Early Signs of Thyroid Problems: https://drruscio.com/what-are-early-warning-signs-of-thyroid-problems/  How to Get Off Thyroid Medication Naturally: https://drruscio.com/how-to-get-off-thyroid-medication/  Thyroid & Hair Loss: https://drruscio.com/thyroid-hair-loss/  Why Your Thyroid Diagnosis Might Be a MISDiagnosis: https://drruscio.com/thyroid-diagnosis/    Timestamps 00:00 Intro to the thyroid   03:57 TSH 05:02 Free T4  05:59 Free T3  07:07 TPO (thyroid antibodies)  08:13 Hashimoto's  10:00 TG (thyroglobulin)  12:58 Defining hypothyroidism 13:27 Defining hyperthyroidism  13:48 The grey area “Sluggish thyroid” 18:07 Treatments  20:20 Where symptoms can come from 24:25 Thyroid lab interpretation guide   Featured Studies  Physiology, Thyroid: https://pubmed.ncbi.nlm.nih.gov/30137850/  Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III): https://pubmed.ncbi.nlm.nih.gov/11836274/  Serum thyrotrophin and circulating thyroglobulin and thyroid microsomal antibodies in a Finnish population: https://pubmed.ncbi.nlm.nih.gov/760358/  The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area: https://pubmed.ncbi.nlm.nih.gov/14558922/  Hypothyroidism Prevalence in the United States: A Retrospective Study Combining National Health and Nutrition Examination Survey and Claims Data, 2009-2019: https://pubmed.ncbi.nlm.nih.gov/36466005/  Correlation between sonography and antibody activity in patients with Hashimoto thyroiditis: https://pubmed.ncbi.nlm.nih.gov/24154902/  Laboratory Testing in Thyroid Conditions - Pitfalls and Clinical Utility: https://pubmed.ncbi.nlm.nih.gov/30215224/  Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment: https://pubmed.ncbi.nlm.nih.gov/35243857/  Anti-Thyroperoxidase Antibody Levels >500 IU/ml Indicate a Moderately Increased Risk for Developing Hypothyroidism in Autoimmune Thyroiditis: https://pubmed.ncbi.nlm.nih.gov/27607246/  Hyperthyroidism: https://pubmed.ncbi.nlm.nih.gov/32206604/  Subclinical Hypothyroidism: https://pubmed.ncbi.nlm.nih.gov/30725655/  Transient high thyroid stimulating hormone and hypothyroidism incidence during follow up of subclinical hypothyroidism: https://pubmed.ncbi.nlm.nih.gov/34879182/  Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis: https://pubmed.ncbi.nlm.nih.gov/30285179/  Treating hypothyroidism is not always easy: When to treat subclinical hypothyroidism, TSH goals in the elderly, and alternatives to levothyroxine monotherapy: https://pubmed.ncbi.nlm.nih.gov/34766382/  Symptoms Originally Attributed to Thyroid Dysfunction Were Instead Caused by Suboptimal Gastrointestinal Health: A Case Series and Literature Review: https://pubmed.ncbi.nlm.nih.gov/35999903/  The Relationship between Gastrointestinal Health, Micronutrient Concentrations, and Autoimmunity: A Focus on the Thyroid: https://pubmed.ncbi.nlm.nih.gov/36079838/  Combined treatment with Myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis: https://pubmed.ncbi.nlm.nih.gov/24224112/  Effects of vitamin D on thyroid autoimmunity markers in Hashimoto's thyroiditis: systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/34871506/  Probiotics Ingestion Does Not Directly Affect Thyroid Hormonal Parameters in Hypothyroid Patients on Levothyroxine Treatment: https://pubmed.ncbi.nlm.nih.gov/29184537/    Get the Latest Updates Facebook - https://www.facebook.com/DrRusciodc Instagram - https://www.instagram.com/drrusciodc/ Pinterest - https://www.pinterest.com/drmichaelrusciodc    DISCLAIMER: The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment or discontinuing an existing treatment. Music featured in this video: "Modern Technology" by Andrew G, https://audiojungle.net/user/andrew_g  *Full transcript available on YouTube by clicking the “Show transcript” button on the bottom right of the video.

Wouldn't it be great to win that Nobel prize in educational rocketsurgery by publishing that great multi-institutional medical education study?! We review a paper on research collaborations looking for tips on how to do it right. Host: Jason FrankEpisode ArticleSbaity, E., Zahwe, M., Helou, V., Bahsoun, R., Hassan, Z., Abi Khalil, P., & Akl, E. A. (2023). Health Research Collaborations by Academic Entities: A Systematic Review. Academic Medicine, 98(10), 1220. https://doi.org/10.1097/ACM.0000000000005277Episode webpageHosts: Lara Varpio, Jason Frank, Jonathan Sherbino, Linda SnellTechnical Producer: Samuel LundbergExecutive Producer: Teresa SöröProduction of Unit for teaching and learning at Karolinska Institutet

Today I talked to Jenni Silverstein and Elizabeth Bechard about their study (co-authored wiht Jennifer Walker) "What are the Impacts of Concern about Climate Change on the Emotional Dimensions of Parents' Mental Health? A Literature Review" published in the Journal of Health Care Communications (September, 2023). Jenni Silverstein is a Licensed Clinical Social Worker and Infant-Family Mental Health Specialist, working at the intersection of Climate Justice and Early Childhood Mental Health.  Elizabeth Bechard is Senior Policy Analyst for Moms Clean Air Force and leads the organization's work on climate change and mental health. She is author of Parenting in a Changing Climate: Tools for Cultivating Resilience, Taking Action, and Practicing Hope in the Face of Climate Change. Karyne Messina is a licensed psychologist and psychoanalyst at the Washington Baltimore Center for Psychoanalysis and am on the medical staff of Suburban Hospital in Bethesda, Maryland. She is the author of Resurgence of Populism: A Psychoanalytic Study of Projective Identification, Blame Shifting and the Corruption of Democracy (Routledge, 2022). Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Today I talked to Jenni Silverstein and Elizabeth Bechard about their study (co-authored wiht Jennifer Walker) "What are the Impacts of Concern about Climate Change on the Emotional Dimensions of Parents' Mental Health? A Literature Review" published in the Journal of Health Care Communications (September, 2023). Jenni Silverstein is a Licensed Clinical Social Worker and Infant-Family Mental Health Specialist, working at the intersection of Climate Justice and Early Childhood Mental Health.  Elizabeth Bechard is Senior Policy Analyst for Moms Clean Air Force and leads the organization's work on climate change and mental health. She is author of Parenting in a Changing Climate: Tools for Cultivating Resilience, Taking Action, and Practicing Hope in the Face of Climate Change. Karyne Messina is a licensed psychologist and psychoanalyst at the Washington Baltimore Center for Psychoanalysis and am on the medical staff of Suburban Hospital in Bethesda, Maryland. She is the author of Resurgence of Populism: A Psychoanalytic Study of Projective Identification, Blame Shifting and the Corruption of Democracy (Routledge, 2022). Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychology

Literature Review this Week 1) From Cell Host and Microbe - "The microbiomes of cesarean-born infants differ from vaginally delivered infants and are associated with increased disease risks. Vaginal microbiota transfer (VMT) to newborns may reverse C-section-related microbiome disturbances. Here, we evaluated the effect of VMT by exposing newborns to maternal vaginal fluids and assessing neurodevelopment, as well as the fecal microbiota and metabolome. Sixty-eight cesarean-delivered infants were randomly assigned a VMT or saline gauze intervention immediately after delivery in a triple-blind manner...... and much more about the cutting edge science of today. Also a piece on napping followed by the recipe of the week. Enjoy, Dr. M    

I cannot believe we are here, where 3 years after the initial "freak out" of Covid19, there are rumors of the re-introduction of protection measures including masks, vaccine(s)/boosters, social distancing and more.While I of course have my opinions, this show is about informed consent, so I think its time we break down the informed consent of some of these "protection" measures for Covid, and the scientific data that supports (or doesn't support) them.In this weeks episode, we dive into the informed consent on the lockdowns and "stay at home orders."Subscribe and hang out with me every Wednesday to stay up to date on this show.  If you enjoy, please share this on your social media and tag me (@brookebacci) and give me a rating/review. Thank you!Sponsors: Magic Mind - productivity and energy shotBROOKE20 to save 56% or use link below to save 20% off your first orderhttps://www.magicmind.com/brookeOrganic Herbal Remedies Use Code BROOKE10 to save 10%https://earthley.com/ref/brookebacci/Sources:https://sites.krieger.jhu.edu/iae/files/2022/01/A-Literature-Review-and-Meta-Analysis-of-the-Effects-of-Lockdowns-on-COVID-19-Mortality.pdfhttps://pubmed.ncbi.nlm.nih.gov/32539153/https://www.pewresearch.org/short-reads/2023/03/02/mental-health-and-the-pandemic-what-u-s-surveys-have-found/https://www.kff.org/mental-health/issue-brief/a-look-at-the-latest-suicide-data-and-change-over-the-last-decade/https://www.medicalnewstoday.com/articles/how-have-pandemic-lockdowns-affected-the-immune-systemhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844019/https://www.lyonspc.com/2023/01/09/impact-covid-divorce-rates/

*Content Warning: child abuse, sibling abuse, emotional, sexual, medical and physical violence of children. Free and confidential resources + Safety Tips: somethingwaswrong.com/resources Artwork by the amazing Sara Stewart @GreaterThanOkay - Instagram.com/greaterthanokay*Sources:Child Welfare Organizations by Statehttps://www.childwelfare.gov/organizations/?CWIGFunctionsaction=rols:main.dspList&rolType=custom&rs_id=5CDC on Child Abuse Prevalencehttps://www.cdc.gov/violenceprevention/childabuseandneglect/vacs/onebillion-children.htmlCDC Fast Facts on Child Abuse https://www.cdc.gov/violenceprevention/childabuseandneglect/fastfact.htmlChild Sexual Abuse Disclosure Rateshttps://www.d2l.org/wp-content/uploads/2020/01/Child-Sexual-Abuse-Disclosure-Statistics-and-Literature-Review.pdfChild Sexual Abuse Prevalence & Statisticshttps://www.d2l.org/wp-content/uploads/2020/01/Updated-Prevalence-White-Paper-1-25-2016_2020.pdfCalifornia Partnership to End Domestic Violencehttps://www.cpedv.org/Children's Assessment Centerhttps://cachouston.org/about-the-cac/a-message-from-our-director/Domestic Violence Action Centerhttps://domesticviolenceactioncenter.org/about/Futures Without Violencehttps://www.futureswithoutviolence.org/our-mission/Child Welfare.gov on The Consequences of Abusehttps://www.childwelfare.gov/pubpdfs/long_term_consequences.pdfChild maltreatment, 19 September 2022, World Health organization https://www.who.int/news-room/fact-sheets/detail/child-maltreatment Peterson C, Florence C, Klevens J. The economic burden of child maltreatment in the United States, 2015. Child Abuse Negl. 2018 Dec;86:178-183. doi: 10.1016/j.chiabu.2018.09.018. Epub 2018 Oct 8. PMID: 30308348; PMCID: PMC6289633. https://pubmed.ncbi.nlm.nih.gov/30308348/ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Literature Review: 1) Is loneliness tied to an increase in death risk? A new study in Nature says yes to a degree of the pooled effect size of 1.32 for all cause mortality. (Wang et. al. 2023) In effect, that is a very large effect of the variable loneliness on death risk. Why would this be? Many reasons come to mind. The greatest of which is the control that our mind wields on our immune system. If we think in negative and in sad terms over a period of time, the immune system will shift into a pro inflammatory state and weakened pathogen killing which has massive downstream effects on physiology. 2) In an impressive inoculation study in the UK, researchers gave the ancestral strain of SARS2 to test subjects and then followed them for 2 weeks in quarantine........ Enjoy Dr. M

I collected my favorite public pieces of research on AI strategy, governance, and forecasting from 2023 so far.If you're a researcher, I encourage you to make a quick list of your favorite pieces of research, then think about what makes it good and whether you're aiming at that with your research.To illustrate things you might notice as a result of this exercise:I observe that my favorite pieces of research are mostly aimed at some of the most important questions[1]– they mostly identify a very important problem and try to answer it directly.I observe that for my favorite pieces of research, I mostly would have been very enthusiastic about a proposal to do that research– it's not like I'd have been skeptical about the topic but the research surprised me with how good its results were.[2]1. Model evaluation for extreme risks (DeepMind, Shevlane et al., May)Current approaches to building general-purpose AI [...] ---Outline:(00:48) 1. Model evaluation for extreme risks (DeepMind, Shevlane et al., May)(02:35) 2. Towards best practices in AGI safety and governance: A survey of expert opinion (GovAI, Schuett et al., May)(04:42) 3. What does it take to catch a Chinchilla? Verifying Rules on Large-Scale Neural Network Training via Compute Monitoring (Shavit, March)(06:53) 4. Survey on intermediate goals in AI governance (Rethink Priorities, Räuker and Aird, March)(09:12) 5. Literature Review of Transformative AI Governance (LPP, Maas, forthcoming)(10:44) 6. “AI Risk Discussions” website: Exploring interviews from 97 AI Researchers (Gates et al., February)(12:46) 7. What a compute-centric framework says about AI takeoff speeds - draft report (OpenPhil, Davidson, January)The original text contained 2 footnotes which were omitted from this narration. --- First published: July 23rd, 2023 Source: https://forum.effectivealtruism.org/posts/zzyD8eTbqj7xairmZ/my-favorite-ai-governance-research-this-year-so-far Linkpost URL:https://blog.aiimpacts.org/p/my-favorite-ai-governance-research --- Narrated by TYPE III AUDIO.

Literature Review - this week we look at topics like: Autism is linked to heart disease!; Machine learning algorithms are going to help us diagnose autism spectrum disorders earlier; Long term gastrointestinal issues post Covid are real and problematical;Celiac disease screening for first degree relatives of a person with celiac disease is warranted;Watching violent video content in early childhood is associated with mental health struggles at age 12 and more... Part two discusses the length of antibiotic needed for pneumonia clearance. And finally a link to a discussion on snakes and bite prevention. Enjoy, Dr. M

If you didn't already know, I do love some good reality T.V. and in this episode we are (mostly) talking about Love is Blind. If you've watched Season 4 I think all I have to say is Zack, Irina, and Bliss and you will know exactly what I'm talking about today... Reality T.V. is entertaining, but it also inadvertently becomes a weird sort of case study. Plenty of shows call authenticity into question whether it's the authenticity of the participants or the authenticity of the show itself. You could give these shows the benefit of the doubt and believe that the people who are casted on these shows are showing you who they are authentically even when the cameras aren't rolling. What happens when it becomes very clear that someone is in fact not being authentic at all? Resources Mentioned: "Why People Ignore Red Flags of Trouble in Relationships" https://www.psychologytoday.com/us/blog/between-the-sheets/202109/why-people-ignore-red-flags-trouble-in-their-relationships "'It's Love Island, Not Friend Island': Authenticity and Surveillance in Reality TV, a Literature Review and Content Analysis" - https://cedar.wwu.edu/cgi/viewcontent.cgi?article=1450&context=wwu_honors Encyclopedia Brittanica - https://www.britannica.com/art/television-in-the-United-States/Reality-TV Psychology in Seattle YouTube Video "Love is Blind - Season 4 #15 - (Zack, Bliss, & Irina) - Therapists Reacts - https://www.youtube.com/watch?v=1W56GyWrZQg --------------------------------------- The Words with Me Podcast is a space for thought and curiosity. It's the mission of the podcast to connect people and cultivate community through insightful conversations on a range of hot topics including healing, growing and being a late bloomer. Life can be hard, so it's important to surround yourself with things and people that affirm and encourage you. If you are looking to enter a space to become the highest version of yourself, check out the Words with Me Podcast! Remember to share, rate and review the podcast. -------------------------------------- Socials: Podcast Instagram: @wordswithmepodcast Personal Instagram: @karstenashleybush Check out my second channel!: https://www.youtube.com/channel/UCTVvZ0PapQR1p6E7bS4w3JA --- Send in a voice message: https://podcasters.spotify.com/pod/show/karsten-bush/message

Receiving information or research that contradicts your beliefs can be discomforting. Place that evidence into the conversation of a controversial subject and the environment is ripe for elevated conflict. What is happening here in the United States? Evidence suggests known risks from drugs may induce violence—contributing to the problem, not solving the problem.If you are in a crisis or think you have an emergency, call your doctor or 911. If you're considering suicide, call 1-800-273-TALK to speak with a skilled trained counselor.RADICALLY GENUINE PODCASTRadically Genuine Podcast Website Twitter: Roger K. McFillin, Psy.D., ABPPInstagram @radgenpodTikTok @radgenpodRadGenPodcast@gmail.comADDITIONAL RESOURCES1:00 - Radically Genuine Podcast | 39. Mass shootings2:00 - Dr. Roger McFillin on Twitter: "It's a bad idea to ignore how many school shooters were on at least 1 psychiatric drug. To ignore the black box warning on antidepressants. To ignore the FDA's adverse event reporting system14:30 - Peter Breggin: Suicidality, violence and mania caused by SSRIs: A review and analysis17:30 - Treatment Emergent Violence To Self And Others; A Literature Review of Neuropsychiatric Adverse Reactions For Antidepressant And Neuroleptic Psychiatric Drugs And General Medications20:00 - Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers24:30 - Psychiatry.org - What is Mental Illness?40:00 - Mirror mirror on the ward, who's the most narcissistic of them all? Pathologic personality traits in health care41:45 - What Is Cognitive Dissonance? Definition and Examples56:00 - SAGE updates COVID-19 vaccination guidance58:00 - Meanings and origin of ‘Judas sheep' and ‘Judas goat' | word histories1:01:30 - Dr. McFillin on Twitter: Why has American health care become pharmaceuticals & psych drugs are pushed on kids? American Academy of Pediatrics. Here is a list of some of their corporate donors

The post Episode 98. Literature Review on TRACE-2 Trial appeared first on The Pharm So Hard Podcast.

Welcome Elizabeth McCormick!  Our newest member of the Ruan Living team sits down with Sophia to discuss how the two are currently applying nontoxic living into their homes and lives. Elizabeth shares her personal journey that led her to nontoxic living, how she and Sophia connected, and what she's currently working on in her home and habits! Enjoy!!  New York City area: Join us at Souk Yoga Studio on Saturday, March 11 for a Ruan Immersion Detox to help you reduce your exposure to EMFs in your home. Reserve your spot today! To join our newsletter, text DETOX to 66866. RESOURCES by RUAN LIVING Shop Amazon—Curated by Ruan D-TOX Academy   Sources about Parabens linked to breast cancer: Literature Review 2016 Study

The Society for Academic Emergency Medicine is pleased to host EMPoweRx at SAEM23. The Emergency Medicine Pharmacotherapy with Resuscitation (EMPoweRx) Conference is an annual international, multidisciplinary conference dedicated to celebrating advancements in research and practice of emergency medicine pharmacotherapy. PACUPrep's BCEMP Q-Bank is the leading edge of emergency medicine and critical care exam preparation. Our […] The post Episode 96. Literature Review on Lidocaine vs Amiodarone in IHCA appeared first on The Pharm So Hard Podcast.

In the December episode of Critical Decisions in Emergency Medicine, Drs. Danya Khoujah and Wendy Chang discuss small bowel obstruction and ileus as well as septic arthritis and gout. As always, you'll hear about the hot topics covered in CDEM's regular features, including acute otitis media in Clinical Pediatrics, an chronic shoulder dislocation in Critical Cases in Orthopedics and Trauma, DixHallpike maneuver in The Critical Procedure, a outpatient stress testing for suspected acute coronary syndrome after a negative workup in the Literature Review, and a toddler with bloody stool in The Critical Image.

Have you suffered with dry skin, brittle nails, extreme fatigue, digestive issues, brittle hair, low mood, and maybe even tingling in your hands and feet? I know you're thinking, well duh.. low thyroid, but what if it's something else? Something simple? What about your thyroid levels are showing too high, yet you have none of the classic symptoms of hyperthyroid? The same vitamin that when deficient can cause skin, hair, and nails issues, can also cause your thyroid blood work to be inaccurate when supplementing in high doses. Listen in to hear all about Biotin. What it is, where you find it naturally, it's role in our body, signs and symptoms of a deficiency, the ins and outs of supplementing with biotin, and how it may also affect thyroid testing. References: Effect of High-dose Biotin on Thyroid Function Tests: Case Report and Literature Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103391/ National Institutes of Health; Office of Dietary Supplements. Biotin: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Biotin-HealthProfessional/. Accessed 6/10/19. Biotin Benefits: What the Experts Have to Say https://health.clevelandclinic.org/benefits-of-biotin/#:~:text=How%20much%20biotin%20do%20you%20need%3F Biotin – Vitamin B7 https://www.hsph.harvard.edu/nutritionsource/biotin-vitamin-b7/#:~:text=An%20RDA%20(Recommended%20Dietary%20Allowance,assumed%20to%20ensure%20nutritional%20adequacy. FDA in Brief: FDA reminds patients, health care professionals and laboratory personnel about the potential for biotin interference with certain test results, especially specific tests to aid in heart attack diagnoses https://www.fda.gov/news-events/fda-brief/fda-brief-fda-reminds-patients-health-care-professionals-and-laboratory-personnel-about-potential Biotin Fact Sheet for Consumers https://ods.od.nih.gov/factsheets/Biotin-Consumer/ Follow Me: Websites: www.coachsandyrobinson.com or www.leanwellonline.com Facebook: https://www.facebook.com/LEANWellonline Instagram: https://www.instagram.com/coachsandyrobinson/ Tiktok: https://www.tiktok.com/@coachsandyrobinson?is_from_webapp=1&sender_device=pc EquiLife Functional Labs and Supplements: https://equi.life?irad=859795&irmp=3421097 Become an Integrative Health Practitioner: https://www.integrativehealthpractitioner.org/?x=CoachSandyRobinson Schedule an appointment with me: https://calendly.com/coachsandyrobinson

Have you suffered with dry skin, brittle nails, extreme fatigue, digestive issues, brittle hair, low mood, and maybe even tingling in your hands and feet? I know you're thinking, well duh.. low thyroid, but what if it's something else? Something simple? What about your thyroid levels are showing too high, yet you have none of the classic symptoms of hyperthyroid? The same vitamin that when deficient can cause skin, hair, and nails issues, can also cause your thyroid blood work to be inaccurate when supplementing in high doses. Listen in to hear all about Biotin. What it is, where you find it naturally, it's role in our body, signs and symptoms of a deficiency, the ins and outs of supplementing with biotin, and how it may also affect thyroid testing. References: Effect of High-dose Biotin on Thyroid Function Tests: Case Report and Literature Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103391/ National Institutes of Health; Office of Dietary Supplements. Biotin: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Biotin-HealthProfessional/. Accessed 6/10/19. Biotin Benefits: What the Experts Have to Say https://health.clevelandclinic.org/benefits-of-biotin/#:~:text=How%20much%20biotin%20do%20you%20need%3F Biotin – Vitamin B7 https://www.hsph.harvard.edu/nutritionsource/biotin-vitamin-b7/#:~:text=An%20RDA%20(Recommended%20Dietary%20Allowance,assumed%20to%20ensure%20nutritional%20adequacy. FDA in Brief: FDA reminds patients, health care professionals and laboratory personnel about the potential for biotin interference with certain test results, especially specific tests to aid in heart attack diagnoses https://www.fda.gov/news-events/fda-brief/fda-brief-fda-reminds-patients-health-care-professionals-and-laboratory-personnel-about-potential Biotin Fact Sheet for Consumers https://ods.od.nih.gov/factsheets/Biotin-Consumer/ Follow Me:  Websites: www.coachsandyrobinson.com or www.leanwellonline.com Facebook: https://www.facebook.com/LEANWellonline Instagram: https://www.instagram.com/coachsandyrobinson/ Tiktok: https://www.tiktok.com/@coachsandyrobinson?is_from_webapp=1&sender_device=pc EquiLife Functional Labs and Supplements: https://equi.life?irad=859795&irmp=3421097 Become an Integrative Health Practitioner: https://www.integrativehealthpractitioner.org/?x=CoachSandyRobinson Schedule an appointment with me: https://calendly.com/coachsandyrobinson

Today, you'll learn about how humans could potentially evolve to be venomous, the challenges of repurposing used electric car batteries, and how people who hate magic are more likely to have certain socially aversive traits, like needing to control social situations.The good and the bad side of snake venom.“Could Humans Ever be Venomous?” by Stephanie Pappashttps://www.livescience.com/could-humans-be-venomous.html“How Snake Venom Kills… and Saves Lives” by James Patersonhttps://letstalkscience.ca/educational-resources/stem-in-context/how-snake-venom-kills-and-saves-lives“Protein Folding: The Good, the Bad, and the Ugly” by Harvard Universityhttps://sitn.hms.harvard.edu/flash/2010/issue65/“This Animal Can Kill 10 Grown Men, But Its Body Adapted To Save Itself” by Tara Yarlagaddahttps://www.inverse.com/science/the-strange-reason-why-poisonous-animals-survive-their-own-toxinsA new era for batteries.“Cars are Going Electric. What Happens to the Used Batteries?” by Gregory Barber and Aarian Marshallhttps://www.wired.com/story/cars-going-electric-what-happens-used-batteries/“Transportation of Electric Vehicle Lithium-ion Batteries at End-of-life: A Literature Review” by Margaret Slattery, Jessica Dunn, and Alissa Kendallhttps://www.sciencedirect.com/science/article/pii/S0921344921003645“Global Implications of the EU Battery Regulation” by Hans Eric Melin, Mohammad Ali Rajaeifar, Anthony Y. Ku, Alissa Kendall, Gavin Harper, and Oliver Heidrichhttps://www.science.org/doi/10.1126/science.abh1416“The Lithium Mine Versus the Wildflower” by Gregory Barberhttps://www.wired.com/story/lithium-mine-for-batteries-versus-the-wildflower/Who hates magic?!“People who hate magic tend to be higher in socially aversive traits, according to new research” By Mane Kara-Yakouabianhttps://www.psypost.org/2022/04/people-who-hate-magic-are-higher-in-socially-aversive-traits-according-to-new-research-62968“Who hates magic? Exploring the loathing of legerdemain.” By Paul J. Silvia et al.https://psycnet.apa.org/record/2022-45549-001Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers.Find episode transcripts here: https://curiosity-daily-4e53644e.simplecast.com/episodes/human-venom-car-battery-blues-magic-and-personalities

Yesterday was the anniversary of Abraham Lincoln signing the House and Senate resolution that later became the 13th Amendment, outlawing slavery in America and federalizing it in our prison system. Awareness is not our virtue these days.  Our live show schedule is hot, so watch out for links to buy tickets, as we are coming to Fort Worth March 16th, Rapid City April 7th, and Phoenix in May. Join the club and you will be first in line! Now I was going to cover Megan Bashan's article “How The Federal Government Used Evangelical Leaders To Spread Covid Propaganda To Churches” but instead I am going to have her on Waterbreak this Thursday night at 7pm, so stand by for that fun interview. https://www.dailywire.com/news/how-the-federal-government-used-evangelical-leaders-to-spread-covid-propaganda-to-churches Abortion Pills Can Now Be Mailed to Your House: Roll Clip https://www.youtube.com/watch?v=Si_EU73j904 (From start to 2min) WaPo article: https://www.washingtonpost.com/nation/2022/01/26/jex-blackmore-tv-abortion-pill/ Sunday on WJBK in Detroit “Let It Rip” host Charlie Langton had a prolife guest on and a pro-abortion guest on to debate “Food and Drug Administration's decision in December to allow abortion pills to be prescribed via telehealth and shipped to patients in the mail”. You know, murder by mail. The pro-abortion advocate, Jex Blackmore, popped a kill pill on air, just listen to this: Roll clip. According to WaPo: “In an email to The Post, Blackmore said her on-air claim was no charade, insisting that she took mifepristone, the first of the two pills, to end a pregnancy. “Abortion is a common and safe medical procedure surrounded by stigma,” Blackmore wrote. “Stigma keeps people silent about their personal experiences and creates space for harmful, inaccurate narratives. My action was intended to dispel some of those myths, misinformation, and stigma.”” My goodness. God is in heaven, we are on earth. God sees all, and we will be held to account for all our unrighteousness. And I am so grateful that God will see me through the blood of Jesus. May God have mercy on Ms. Blackmore. Coming To Grips With the Facts About Masks Coming To Grips With the Facts About Masks James Agresti, wrote a nice piece aggregating all the masking shenanigans and quoting real scientist that have studied the ineffectiveness of masking. Here are a number of quotes he includes from “scientist”: Dr. Vinay Prasad—an associate professor of epidemiology and biostatistics at the University of California, San Francisco— concluded that: -“most of the masks worn by most kids for most of the pandemic have likely done nothing to change the velocity or trajectory of the virus.” -“there are downsides to face coverings for pupils and students, including detrimental impacts on communication in the classroom.” -“masking is now little more than an appealing delusion.” decisions to mask schoolchildren are “ignorant, cruel, fearful, and cowardly.” Dr. Chad Roy, who specializes in airborne infectious diseases and is a professor of microbiology and immunology at Tulane University School of Medicine, has told the Washington Examiner that: -“cloth and surgical masks do absolutely nothing for protection from ambient virus.” -“all this song and dance of wearing cloth masks with some presumption that you're being protected from ambient virus is completely and positively 100% counter to how masks and respirators work.” Dr. Margery Smelkinson, a specialist in infectious diseases at the National Institutes of Health said: “Imposing on millions of children an intervention that provides little discernible benefit, on the grounds that we have not yet gathered solid evidence of its negative effects, violates the most basic tenet of medicine: First, do no harm.” John Hopkins just released this doozie. They did a study on the effectiveness of lockdowns, and guess what! They found lockdowns dont work. Surprise “An analysis of each of these three groups support the conclusion that lockdowns have had little to no effect on COVID-19 mortality. More specifically, stringency index studies find that lockdowns in Europe and the United States only reduced COVID-19 mortality by 0.2% on average. SIPOs were also ineffective, only reducing COVID-19 mortality by 2.9% on average. Specific NPI studies also find no broad-based evidence of noticeable effects on COVID-19 mortality. “ See here for the study: https://sites.krieger.jhu.edu/iae/files/2022/01/A-Literature-Review-and-Meta-Analysis-of-the-Effects-of-Lockdowns-on-COVID-19-Mortality.pdf Brian Flores Sues NFL, Teams Over the Treatment of Black Coaches https://www.wsj.com/articles/brian-flores-lawsuit-racism-bill-belichick-text-messages-11643752620 According WSJ: “Brian Flores, the recently fired coach of the Miami Dolphins, has filed a lawsuit against the National Football League and three specific teams, alleging that Black coaches such as himself are discriminated against in pursuing coaching opportunities. Flores was dismissed by the Dolphins after three years and back-to-back winning seasons. The 40-year-old coach was hired by Miami in 2019 after more than a decade working on the staff of the New England Patriots. The explosive suit figures to reinvigorate debate around the league's diversity hiring efforts and comes after years in which race has been a lightning rod in America's most popular sport. The NFL has long faced criticism over the dearth of Black coaches and executives in a sport in which well over half of the players are Black. The league presently has just one Black head coach, although a number of jobs remain open. The lawsuit, filed in the U.S. Southern District Court of New York on behalf of Flores and seeks to establish a class-action on behalf of others similarly situated, includes a wide-ranging series of allegations covering Flores's time with Miami and his efforts to get other jobs. It accuses teams, including the New York Giants, of giving him token interviews in order to comply with the league's “Rooney Rule,” which requires that franchises interview Black candidates for head coaching and general manager openings.” This is how unjust or silly rules, like the Rooney Rule, go. They set out to solve a problem, but end up creating more problems and greater injustices. We have talked about the Rooney Rule before on our show. I have no doubt Flores was interviewed, just because a team had to meet the one black interview quota. Speaking of solving problems, this is the greatest mocumentary of I seen this year so far: This hilarious. Trans-Racial